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Abstract
Stress induced hyperglycaemia is prevalent in critical care. Since the landmark
paper published by Van den Berghe et al. (2001) a great deal of attention has
been paid to intensive insulin therapy in an ICU setting to combat the adverse
eects of elevated glucose levels and poor glycaemic control. Glycaemic control
protocols have been extensively developed, tested and validated within an ICU
setting. However, little research has been conducted on the eects of a glycaemic
control protocol in a less acute ward setting. There are many additional challenges
presented in a ward setting, such as the variation in meals and levels of activity
between patients, from day to day and throughout the day.
A simple compartment model is used to describe the nature of insulin and
glucose metabolism in patients of the Cardiothoracic Ward (CTW). A stochas-
tic model of the tted insulin sensitivity parameter is generated for this cohort
and validated against cohorts of similar characteristics. The stochastic model
is then used to run simulations of predictive control on 7 CTW patients, which
shows signicantly tighter glucose control than what is obtained with regular
clinical procedures. However, the rate of severe hypoglycaemia is an unaccept-
ably high 4.2%. The greatest challenge in maintaining tight glycaemic control in
such patients is the consumption of meals at irregular times and of inconsistent
quantities.
Insulin sensitivity was compared to extensive hourly clinical data of 36 ICU
patients. From this data a sepsis score of value 0-4 was generated as gold standard
marker of sepsis. Comparing the sepsis score to insulin sensitivity found that
insulin sensitivity provides a negative predictive diagnostic for sepsis. High insulin
sensitivity of greater than SI = 8  10
 5 L mU 1 min 1 rules out sepsis for the
majority of patient hours and may be determined non-invasively in real-time
from glycaemic control protocol data. Low insulin sensitivity is not an eective
diagnostic, as it can equally mark the presence of sepsis or other conditions.
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Chapter 1
Introduction
The benets of glycaemic control in hospitalised and ambulatory patients, such
as a reduction mortality, morbidity and length of stay has been extensively in-
vestigated (Van den Berghe et al., 2001, 2006b,a; Goldberg et al., 2004b,a; Chase
et al., 2006c; Clayton et al., 2006; Collier et al., 2005; Garg et al., 2007; Krinsley,
2003a,b, 2004; Langouche et al., 2007; Laver et al., 2004; Plank et al., 2006; Zerr
et al., 1997). This research was prompted by Van den Berghe et al. (2001) who
found a 42% reduction in mortality among a critically ill cohort with intensive
insulin therapy (IIT). The benets found are largely attributed to a reduction
in hyperglycaemia. In particular, many studies in critically ill cardiac and car-
diothoracic patients have also seen signicant improvements in patient outcome
using intensive insulin therapy (Goldberg et al., 2004c; Malmberg et al., 1995).
However, the methods of maintaining glycaemic control for less acutely ill patients
and the benets from such control have not been fully explored.
This research is aimed at developing insulin sensitivity tools for use in Christchurch
Hospital, with particular emphasis on glycaemic control in the less acute wards
within the hospital. Christchurch Hospital already has the paper based glycaemic
control protocol SPRINT in place as a nearly established protocol in the Inten-
sive Care Unit (ICU) (Chase et al., 2006c; Lonergan et al., 2006b,a), however
the 1-2 hourly measurements required to obtain tight glycaemic control would be
excessively burdensome within a ward.
The incidence of Type II diabetes is disproportionately high in critical care
(). Even so, diabetes is rapidly becoming one of the most common, preventable
and manageble diseases, particularly in the developed world (Wild et al., 2004).
It has been estimated that 2.8% of the adult population suered from diabetes
in 2000 (Wild et al., 2004) and this is expected to rise (Wild et al., 2004; King
et al., 1998). New Zealand is not exempt from this trend and some 68,000 people
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were found to have diabetes in 2000 (Wild et al., 2004). Thus, developing means
of maintaining good glycaemic control will have increasing importance and in the
years to come.
Pharmacokinetic models of the insulin-glucose system have been used to trial,
test and devlop both glycaemic control strategies and glucose tolerance tests and
clinical trials have shown good correspondence with predicted outcomes (Loner-
gan et al., 2006b,a; Chase et al., 2006a; Lotz et al., 2006b,a; Lin, 2007). The use
of such models is a safe way of investigating control strategies. A validated, ac-
curate and simple model will also be highly benecial in developing any real time
control tools, although presently such technologies are limited by measurement
accuracy and ease. However, such models can provide real time estimates of in-
sulin sensitivity data, which could potentially be used to asses patient condition.
Chapter 2
Background
2.1 Metabolism during Illness
The body's main source of energy is glucose, which once sourced from the diet is
stored as glycogen. It is circulated through the bloodstream at a concentration
typically 4-6 mmol L 1. Under healthy physiological conditions the constant
supply of glucose to muscle cells and adipose cells and other cells throughout the
body is regulated by the hormone insulin and sourced from glycogen and stored
protein.
Insulin is a peptide hormone sythesized and secreted by the -cells in the
islets of langerhans which are located in the pancreas. Insulin promotes glucose
uptake and utilization by cells not located in the central nervous system, which
has the eect of lowering plasma glucose levels. High insulin levels also promote
the storage of glucose as glycogen. Glycogen is stored in all cells, but is found in
highest concentrations in the liver and muscle cells. Insulin release is triggered
in response to increased blood glucose levels, such as those encountered after
consumption of a meal.
When the blood glucose levels fall, such as between meals, the -cells of the
islets of langerhans will produce glucagon, which induces glycogenolysis in order
to maintain healthy glucose levels. Glycogenolysis is the process of converting
stored glycogen into glucose and takes place in the liver.
In the periods of fasting, glucose supply is maintained by gluconeogenesis
and fat oxidation. Gluconeogenesis is the production of glucose from amino
acids, lactate and glycerol and takes place primarily in the liver, although the
kidneys also contribute approximately 10% of the total output. This process is
stimulated by low blood glucose levels and suppressed by high levels of insulin.
In a diabetic patient or patient under physiological stress, gluconeogenesis is
often overstimulated resulting in hyperglycaemia. Under physiological stress, the
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catabolism of lipids and protein as a fuel is also increased. Lipid metabolism
is also stimulated by uncontrolled diabetes or prolonged starvation, however,
circulating insulin supresses this mechanism.
When the periods between meals are extended, such as in the case of a CTW
patient suering the the eects of treatment or surgery, this mechanism becomes
more dominant than normally encountered in everyday life. The use of cate-
chloamines, vasoconstrictors and glucocorticoids also contribute to overstimula-
tion of gluconeogenesis. If fasting is prolonged beyond 2 days, glucose supply to
the brain is sourced from the production of hepatic ketone bodies, which then
inhibits gluconeogenesis fuelled by muscle tissue (Chiolero et al., 1997).
2.2 Diabetes and Glycaemic Control
There are two primary forms of diabetes, with varying levels of severity. A patient
with Type I diabetes has no -cell function and must inject exogenous insulin in
order to maintain glycaemic control, thus the term 'Insulin Dependent Diabetic'.
A patient with Type II diabetes displays reduced cellular responsiveness to insulin
throughout the body as well as reduced response to heightened levels of insulin.
Reduced insulin sensitivity observed in Type II diabetes is most commonly caused
by poor diet consisting of a high concentration of carbohydrate (CHO) rich foods
or foods with high sugar content. Type II diabetes can typically be managed with
healthy eating and exercising habits combined with weight loss, but is rapidly
becoming a common disorder throughout developed nations (DPPRG, 2002).
The use of oral hypoglycaemics, such as thiazolidinediones, biguanides or
sulfonylureas are used to increase insulin sensitivity of patients exhibiting high
resistance to insulin. The use of such medications enables patients with Type
II diabetes to reduce or eliminate the need for exogenous insulin. However, a
2002 study found that healthy lifestyle changes in the form of increased physical
activity and improved diet resulted in a much larger reduction in the incidence of
Type II diabetes than those recieving the oral hypoglycaemic, Metformin (DP-
PRG, 2002).
Glycaemic control has been recognised as an important part of reducing the
serious complications associated with diabetes, such as retinopathy, neuropathy,
cardiac dysfunction and reduced resistance to infection. Glycaemic control is
commonly measured by levels of Haemoglobin A1c (HbA1c) in the blood, which
reects the concentrations of glucose which have been present over the lifecycle
of haemoglobin (approximately 180 days) (Bennett et al., 2007). Healthy levels
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of HbA1c are between 4-6%, although many diabetics target a value below 7%.
Currently, the World Health Organisation (WHO) does not recognise this as a
diagnostic tool for diabetes.
When determining post-prandial insulin doses, a diabetic patient typically
estimates the quantity of carbohydrates in the meal to estimate the required
insulin input. The ratio of insulin:CHO is dependent on the extent of -cell
impairment, but typically ranges from 1:8-1:32.
It has been suggested that the creation of an articial pancreas will allow
diabetes suers to maintain healthy blood glucose levels with minimal risk and
increased ease (Teixeira and Malin, 2008). However, the control achieveable with
such technology remains unsatisfactory, largely due to the absence of reliable a
continuous glucose monitor (CGM). A CGM tests glucose levels intermittently
using samples from the interstitium, however the error in the measurements is
much greater than that found in nger prick measuring equipment (Nichols et al.,
2007). Thus, ambulatory patients are currently limited to the use of insulin
pumps or manual insulin administration to obtain good glycaemic control.
However, signicant advances in glycaemic control for ambulatory diabetes
have been made, particularly with the use of insulin glargine. Glargine is a
long acting insulin which has no pronounced peak action and a short rise time.
It acts continuously over a 24 hour period, thus allowing a single daily dose
for basal insulin secretion replacement. Glargine has been found to have similar
benets as neutral protamine Hagedorn (NPH) insulin, although there is evidence
that the use of glargine results in lower HbA1c levels and reduced night-time
hypoglycaemia than NPH (Wang et al., 2007; Fritsche et al., 2003; Wang et al.,
2003; Yki-Jrvinen et al., 2006). The cause of the hypoglycaemia is likely due
to the more pronounced peak of NPH, which could also result in higher average
glucose levels.
Several studies using the Holman and Turner algorithm ? for insulin titra-
tion (refer to Equation 2.2) have been conducted with and without oral hypo-
glycaemics ??. Using this algorithm on Type II diabetics, along with a regular
dose of glimepiride (a suonylurea), Fritsche found that a regular morning dose of
glargine signicantly reduced HbA1c levels compared to evening doses of glargine
or NPH. However, all interventions demonstrated a reduction in fasting blood
glucose and HbA1c levels (Fritsche et al., 2003).
Insulin Dose =
GE   50
10
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Where GE is the fasting plasma glucose level in mg dl
 1.
Other titration schemes involve similar sliding scale adjustments to insulin
dose based on fasting glucose levels (?Riddle et al., 2003; Davies et al., 2005).
Studies in which insulin doses are guided by patient or physician/investigator
experience rather than by a specic formula have observed similar benets from
targeted glucose control. However, all of these were designed around dose adjust-
ment occuring at frequencies between 2 days and one week. Because the average
length of stay of a patient in the CTW is of the order of one week, such systems
will not have reached a nal balance by the time of discharge. Similarly, they
are not dynamic enough to accomodate the rapid changes in patient condition or
daily routine which may occur in a ward.
Strange suggests that once basal insulin titration has been conducted for 12
weeks, the optimal basal dose will have been found and then meal boluses should
be investigated (Strange, 2007). However, in a CTW environment, patients need
targeted glycaemic control in the short term, so while such methods may im-
prove ambulatory diabetic care, such considerations are beyond the scope of this
research.
2.3 Insulin and Intensive Insulin Therapy
Stress induced hyperglycemia is prevalent in critical care, and can occur in pa-
tients with no history of diabetes (Capes et al., 2000; Van den Berghe et al., 2001;
Mizock, 2001; McCowen et al., 2001). Critically ill patients exhibit increased en-
dogenous glucose production, reduced insulin production, and increased insulin
resistance (Mizock, 2001; McCowen et al., 2001; Doran, 2004). Excessive enteral
feeding of glucose and administration of glucocorticoids can further exacerbate
hyperglycemia (Patino et al., 1999; Ahrens et al., 2005; Krishnan et al., 2003).
Hyperglycemia worsens outcomes leading to risk of further complications,
particularly sepsis (Bistrian, 2001), myocardial infarction (Capes et al., 2000),
and polyneuropathy and multiple organ failure (Van den Berghe et al., 2001)
as well as increased length of stay (Garg et al., 2007). Van den Berghe et al.
(2001, 2003, 2006b) showed that tight glucose control averaging 5.7-6.0 mmol/L
reduced ICU mortality 18-45% for patients with greater than 3 days stay. Krinsley
(2003b, 2004) showed a 17-29% reduction in mortality with a higher glucose
limit of 7.75 mmol/L. These studies detail the clinical signicance of maintaining
normoglycemia, and indicate that elevated glucose levels outside the target range
are associated with poorer outcomes (Krinsley, 2003a; Van den Berghe et al.,
2.3 INSULIN AND INTENSIVE INSULIN THERAPY 7
2003; Collier et al., 2005). Tight control also minimises rebound hyperglycaemia
on discharge to the wards (Krinsley, 2003b) and minimises development of (new)
infections due to elevated blood glucose (Krinsley, 2003a, 2004; Goldberg et al.,
2004b).
Clinical studies that did not include mortality endpoints include those by
Goldberg et al. (2004b), Laver et al. (2004) and Thomas et al. (2005). A compar-
ison of SPRINT to these protocols has been completed using virtual trials and
retrospective patient data by Lonergan et al. (2006b). This study showed that
SPRINT provided tighter control and higher time in glycaemic control bands
(Lonergan et al., 2006b).
Malmberg et al. (1995) found that a insulin-glucose infusion resulted in a
29% reduction in 1-year mortality among diabetic patients following a myocardial
infarction. For patients who had not previously recieved insulin, the reduction in
1-year mortality was 52%.
Adaptive model-based protocols for insulin-mediated glucose control have
shown promise, but have limitations with respect to easy implementation and
complexity (Ahrens et al., 2005; Krishnan et al., 2003; Bistrian, 2001; Van den
Berghe et al., 2003) The SPRINT protocol satised the need for a simple and
easily implemented means of getting the eectiveness of computerised, model-
based protocols into long term clinical testing. SPRINT was developed to mimic
eective model-based methods (Van den Berghe et al., 2003, 2006b), and is unique
in its use of both insulin and nutrition inputs for tight glycaemic regulation.
Poor glycaemic control is caused reduced ability to maintain safe levels by
normal physiological reactions to elevated glucose levels. The physiological stress
of surgery or illness may also induce a signicant inammatory response which
causes insulin resistance (Virkamaki and Yki-Jarvinen, 1994). Combined with
increased endogenous glucose production (Chambrier et al., 2000), the patient
may experience signicant hyperglycaemia. The reduction of these dangerous
glucose levels, as well as the anti-imammatory eects of insulin, are the most
likely reasons for the success of IIT.
Hypoglycaemic events are the biggest risk of insulin therapies. If large doses
are administered without regular measurement of glucose levels the patient is
put at risk. This is particularly true when dealing with patients who have a pre-
existing diabetes as they may not recognise that they have become hypoglycaemic
due to repeated exposure to low glucose levels, which builds up a resistance to
the symptoms (Boyle et al., 1995).
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2.4 Sepsis and Insulin Sensitivity
Sepsis has a mortality rate of 40-50% (Tsiotou et al., 2005; Esteban et al., 2007)
and occurs in 11.8% of ICU patients in Australasia (Finfer et al., 2004). Sepsis
dened by the presence of two or more symptoms of Systemic Inammatory
Response Syndrome (SIRS) and infection. SIRS is dened by the presence of one
or more of the following:
 body temperature greater than 38 or less than 36
 heart rate greater than 90 beats per minute
 hyperventilation, a respiratory rate greater than 20 min 1 or a PaCO2 of
less than 32 mmHg
 a white blood cell count of greater than 120000 cells l 1 or less than 4000
cells l 1
Severe sepsis is said to be dened by the above criteria for sepsis as well as organ
dysfunction, hypoperfusion or hypotension. Severe sepsis becomes classied as
septic shock when hypotension remains pronounced (systolic arterial pressure <
90 mmHg or mean arterial pressure (MAP) < 60) in spite of uid resuscitation.
(Tsiotou et al., 2005)
The inammatory response to such widespread infection causes vasodilation
and fever as well as increasing endogenous glucose production. The inammation
is caused by Interleukin-1 (IL-1) and tumor necrosis factor- (TNF-). The use
of both of these biomarkers has been used as a diagnostic test with limited suc-
cess. Positive blood cultures however, while denitive, take too long to process
to maintain clinical applicability and thus sepsis remains dicult to positively
identify with certainty. There is a documented relationship between insulin re-
sisitance (S 1I ) and infection (Virkamaki and Yki-Jarvinen, 1994; Rassias et al.,
1999) however the relationship between real time identied insulin sensitivity
metrics has not been related to a diagnosis of sepsis. The accurate identication
of sepsis is an important clinical problem because the overuse of antibiotics leads
to antibiotic resistant bacteria.
2.5 Pharmacokinetic Models
Identifying insulin sensitivity requires capturing the fundamental dynamics of
the glucose regulatory system. The minimal model of Bergman (1979; 1981;
1987; 2005) encapsulates the essential insulin-glucose dynamics through the use
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of 3 compartments. This model has been adapted to best suit the cohort being
considered. Two important variations of the model are discussed here.
2.5.1 ICU Model
Chase et al. (2006c); ? and Lonergan et al. (2006b,a) used the system described by
Equations 2.1-2.5. This model has been applied to an ICU cohort in Christchurch
Hospital with signicant success in model-based and paper-based glycaemic con-
trol clinical trials. Extensive validation of the model has also been carried out.
_G =  pGG 
SI(G+GE)Q
1 + GQ
+ P (t) (2.1)
_Q =  kQ+ kI (2.2)
_I =  
nI
1 + II
+
uex
V
+
IBe
 uex
V
(2.3)
P (ti < t < ti+1) = Pi+1 + ( Pi   Pi+1)e
 kpd(t ti) where Pi+1 < Pi (2.4)
P (ti < t < ti+1) = Pi+1 + ( Pi   Pi+1)e
 kpr(t ti) where Pi+1 > Pi (2.5)
Where G(t) [mmol/L] is the plasma glucose above an equilibrium level, and
I(t) [mmol/L] is the plasma insulin resulting from exogenous insulin input, uex(t)
[mU/min]. The eect of previously infused insulin being utilised over time is rep-
resented by Q(t) [mU/L], with k [1/min] accounting for the eective life of insulin
in the system. Patient endogenous glucose clearance and insulin sensitivity are
pG [1/min] and SI [L/(mU.min)], respectively. The parameter V [L] is the insulin
distribution volume and n [1/min] is the constant rst order decay rate for in-
sulin from plasma. Total plasma glucose input is denoted P (t) [mmol/(L.min)].
Endogenous insulin production is given by IB [mU/min]. Michaelis-Menten func-
tions are used to model saturation, with I [L/mU] used for the saturation
of plasma insulin disappearance, and G [L/mU] for the saturation of insulin-
dependent glucose clearance. kpr and kpd are the eective half lives of glucose
transport from gut to plasma for both increasing and decreasing feed rates re-
spectively, and Pi and Pi+1 are the steps in enteral glucose feed rates. Generally,
k; kpr; kpd; n; G; I and V are set to generic population values.
2.5.2 Ambulatory Diabetic Model
Ambulatory diabetics recieve a wide variety of insulins through the subcutaneous
route. Wong (?2008; 2008) developed a ve compartment model which describes
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the action of many of these insulins following administration and their decompo-
sition into hexameric and dimeric/monomeric state. The insulins considered in
this model are:
 RI - a short acting insulin
 MI - a short acting insulin
 NPH - an intermediate acting insulin
 lente - an intermediate acting insulin
 ultralente - a long acting insulin
 glargine - a long acting insulin
Equations 2.6-2.14 dene the absorption kinetics.
_xi(t) =  (k3 + kd;i)xi(t) + k2xdm(t) (2.6)
_xh(t) =  (k1 + kd)xh(t) + kcrys;NPHcNPH(t) + kcrys;lenclen(t) + uh;RH(t):::
+uh;NPH(t) + uh;len (2.7)
_xdm(t) =  (k2 + kd)xdm(t) + k1xh(t) + k1;ulenxh;ulen(t) + k1;glaxh;gla(t) + umono(t):::
+um;RHt(t) + um;NPH(t) + um;len(t) + um;ulen(t) + um;gla(t) (2.8)
_cNPH(t) =  kcrys;NPHcNPH(t) + uc;NPH(t) (2.9)
_clen(t) =  kcrys;lenclen(t) + uc;len(t) (2.10)
_xh;ulen(t) =  (k1;ulen + kd)xh;ulen(t) + kcrys;ulenculen(t) + uh;ulen(t) (2.11)
_culen(t) =  kcrys;ulenculen(t) + uc;ulen(t) (2.12)
_xh;gla(t) =  (k1;gla + kd)xh;gla(t) +min(kprep;glapgla(t); rdis;max) + uh;gla(t) (2.13)
_pgla(t) =  min(kprep;glapgla(t); rdis;max) + up;gla(t) (2.14)
Where:
xi is mass in the interstitium compartment [mU]
xh is mass in the hexameric compartment [mU]
xh;ulen is mass in the ultralente hexameric compartment [mU]
xh;gla is mass in the glargine hexameric compartment [mU]
xdm is mass in the dimer/monomer compartment [mU]
cNPH is mass in the NPH crystalline protamine compartment [mU]
clen is mass in the lente crystalline zinc compartment [mU]
pgla is mass in the glargine precipitate compartment [mU]
k1 is hexamer dissociation rate [min
 1]
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k1;ulen is ultralente hexamer dissociation rate [min
 1]
k1;gla is glargine hexamer dissociation rate [min
 1]
k2 is dimeric/monomeric insulin transport into interstitium [min
 1]
k3 is interstitium insulin transport rate into plasma [min
 1]
kd;i is rate of loss from interstitium [min
 1]
kd is rate of diusive loss from hexameric and dimeric/monomeric state
compartments [min 1]
kprep;gla is glargine precipitate dissolution rate [min
 1]
kcrys;len is lente zinc crystalline dissolution rate [min
 1]
kcrys;ulen is ultralente zinc crystalline dissolution rate [min
 1]
kcrys;NPH is NPH protamine crystalline dissolution rate [min
 1]
rdis;max is maximum glargine preciptate dissolution rate [mU min
 1]
uh is RI hexamer state insulin input [mU min
 1]
uh;NPH is NPH hexamer state insulin input [mU min
 1]
uh;len is lente hexamer state insulin input [mU min
 1]
uh;ulen is ultralente hexamer state insulin input [mU min
 1]
uh;gla is glargine hexamer state insulin input [mU min
 1]
umono is MI dimer/monomer state insulin input [mU min
 1]
um;RH is RI dimer/monomer state insulin input [mU min
 1]
um;NPH is NPH dimer/monomer state insulin input [mU min
 1]
um;len is lente dimer/monomer state insulin input [mU min
 1]
um;ulen is ultralente dimer/monomer state insulin input [mU min
 1]
um;gla is glargine dimer/monomer state insulin input [mU min
 1]
The model above has been validated against various pharmacokinetic studies
nding good correspondence between almost all predicted peak values and target
data (?Wong et al., 2008; Wong, 2008).
2.5.3 Parameter Identication using the Integral Fitting
Method
The integral tting method of Hann et al. (2005) has been extensively used for
parameter identication of long term pharmacokinetic models (Lonergan et al.,
2006a; ?). The integral tting method is convex and generates a linear system to
be solved. An analysis of the error introduced into the method by approximating
the glucose curve as a piecewise linear prole (refer to Equation 2.15) found
that no additonal error is introduced by the tting process. This is shown by
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Equations 2.16 and 2.17, which are the two patient specic terms of the error term
introduced. As shown, both are of the order  (a measure of the best possible t)
which is not aected by the glucose data approximation. Note that this analysis
is for the application of the method to the ICU model, where both SI and pG are
tted parameters.
0  j(t)j   where G(t)T;real = G(t)T;approx + (t) (2.15)
pG(t  t0)
pG
R t
t0
GT;real(t)dt
 <
(t  t0)R t
t0
1dt
=  where GT;real = 1 (2.16)

SI(t  t0)
SI
R t
t0
GT;real(t) Q(t)dt
 <

R t
t0
Q(t)R t
t0
Q(t)dt
=  where GT;real = 1 (2.17)
(2.18)
2.5.4 Stochastic Modelling
Lin et al. (2008) used a stochastic model to describe the characteristics of an
ICU population. Because SI is a Markov variable, the probability of SI;n+1 = y
is dened by the previous state, SI ; n, as shown in Equation 2.19.
p(SI;n+1 = yjSI;n = x) =
p(SI;n = x; SI;n+1 = y)
p(SI;n = x
) (2.19)
The probabilities required in Equation 2.19 are dened by the available clin-
ical data, using Equation 2.20.
p(x; y) =
1
n
nX
i=1
ffi(x;xi; ff
2
xi
)
pxi
ffi(y; yi; ff
2
yi
)
pyi
(2.20)
pxi =
Z
1
0
ffi(x;xi; ff
2
xi
) (2.21)
pyi =
Z
1
0
ffi(y; yi; ff
2
yi
) (2.22)
Where xi and yi represent the SI;n and SI;n+1 pairs in the clinical data.
The ffi(x;xi; ff
2
xi
) term represents a non-negative normal probability distribution
function centered at xi and similarly for yi. Integrating Equation 2.20 gives
Equation 2.23.
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p(x) =
Z
p(x; y)dy =
1
n
nX
i=1
ffi(x;xi; ff
2
xi
)
pxi
(2.23)
Thus, Equation 2.19 can be written as shown in Equations 2.24 and 2.25.
p(SI;n+1 = yjSI;n = x) =
nX
i=1
!i(x)
ffi(x;xi; ff
2
xi
)
pxi
(2.24)
!i(x) =
ffi(x;xi;ff
2
xi
)
pxiPn
j=1
ffi(x;xj ;ff2xj )
pxj
(2.25)

Chapter 3
Cohort Data
3.1 CTW Patient Data
Glycaemic control data from patients experiencing hyperglycaemia in the CTW
of Christchurch Hospital in the year 2007 was gathered for this study. Patients
in the CTW typically have a one week turnaround and there are 10 beds. Ethics
approval from the South Island Regional Ethics Committee was obtained for this
research.
Obtaining glycaemic control data for patients in the CTW presented signif-
icant challenges. Only patients recieving insulin were of interest because these
are patients that have experienced poor glucose control and thus reect the tar-
get population for new glycaemic control strategies. In addition, patients not
recieving exogenous insulin cannot be as accurately modelled as those who are
due to the unknown endogenous metabolic response to such inputs. Without
exogenous insulin, all glucose regulation is performed by endogenous production
of insulin and glucose,and its endogenous clearance of the same. These processes
cannot be accurately modelled without further, high density, clinical data, such
as C-peptide levels, over time that are not available in this case.
The primary diculty in data collection was accurately determining the se-
lected patients' carbohydrate intake. Patients in the CTW eat hospital meals, as
well as food brought in from outside of the hospital. Generally, no detailed record
of food consumed is kept. To enable a study cohort to be modlled, nurses in the
CTW kept a record of hospital meals ordered and the proportion consumed for
those patients recieving insulin. Using nutritional data from Christchurch Hos-
pital, the carbohydrate value of patient meals could be calculated and adjusted
to the portion eaten.
However, several errors are inherent in this method. There is a discretisation
error as the proportion consumed was only recorded as 0%, 25%, 50% 75% or
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Figure 3.1 Distribution of blood glucose measurements from all 7 patients of the CTW
cohort. The tted probability density function assumes a lognormal distribution
100%. There is also a degree of subjective judgement involved in recording a
proportion consumed, which may vary between nurses. Finally, the proportion
consumed does not take into account which particular foods in a meal were con-
sumed. For example, if 50% of a meal was consumed, this does not necessarily
mean that 50% of carbohydrates in that meal was consumed. A patient may
select the carbohydrate rich foods, or avoid those foods depending on tastes.
Finally, errors in the documentation process were also present. Diculties oc-
cured with meal times being ommitted from recorded data. If such cases ocurred
in isolation and the rest of the data was of high quality, an estimate of the time
of consumption could be made based on regular meal times and glycaemic data.
Where data measurements were largely vague or inaccurate, the entire data set
for that period had to be excluded, further limiting the amount of useable data.
Figure 3.1 shows the blood glucose data for the CTW cohort. There is a high
mean value and mode, which is indicative of the fact that the patients included
are those who require glycaemic control. The data does not necessarily cover a
patient's entire stay in the CTW, but represents dierent stages of the recovery
process. The quality of data available dictated the periods that have been selected
for investigation was not dependent on the time spent in the CTW. Periods of
no insulin administration were omitted. However, these omitted periods are not
reected in any of the statistics presented.
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3.1.1 Cohort Statistics
A total of 7 sets of patient data were of sucient quality to be used in this study,
comprising a total of 278 blood glucose measurements over 744 hours (approxi-
mately 1 measurement every 2.6 hours). After some sections of poor data quality
were removed, the remaining number of patient hours was 692 which included
269 glucose measurements (approximately 1 measurement every 2.6 hours). The
summary statistics for this cohort are shown in Tables 3.1 and 3.2. Full cohort
details are shown in Table 3.3.
Mean IQR1 SD2
Length of Data Series 98.9 63.8-113.0 47.5
Age 69.4 65.0-75.3 7.9
Sex (% Male) 71 - -
1 Inter-quartile range
2 Standard deviation
Table 3.1 Summary statistics of CTW patient data
Median Blood Glucose during stay (mmol L 1) 8.9
Blood Glucose standard deviation (mmol L 1) 3.8
BG readings below 4 mmol L 1 (%) 2.2
BG readings above 6 mmol L 1 (%) 88.5
BG readings above 7 mmol L 1 (%) 79.9
BG readings above 7.75 mmol L 1 (%) 69.1
BG readings above 10 mmol L 1 (%) 37.2
Table 3.2 Summary statistics of CTW patient glycaemic control data
The ratio between number of measurements and hours of data varies signi-
cantly between patients. High data density is ideal because it allows identication
of higher frequency changes in insulin sensitivity over time and thus gives a better
approximation to the likely true patient behaviour. Large insulin doses also en-
able more accurate ts. Overall, the cohort also has entirely diagnosed diabetes
which is one likely reason for the generally greater measurement frequency.
It is important to remember that the cohort includes only CTW patients
experiencing glycaemic control problems and does not represent typical CTW
characteristics overall. However, the patients included in the cohort are those
who would likely benet from any control technologies that are developed. Thus
it is created for protocol design, rather than representing a specic unit.
Patient 7 had a period of 34 hours in which no meal data is available. It is
uncertain whether no meal was eaten during this time or if data was not recorded,
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however the latter case is most likely based on the data. For this reason, the last
54 hours of data was removed from the study. The data in Tables 3.1-3.3 reects
this ommission.
Using the methods and model described in Chapter 4, an SI prole was t
for the entire set of data available, including the last 54 hours for Patient 7. The
errors in this t due to reaching imposed upper and lower limits on SI were then
corrected for by tting a new glucose input curve. This curve closely follows the
modelled glucose input from the CHO content of CTW meals, with three notable
exceptions marked by arrows in Figure 3.2.
The rst is during the middle of the 34 hour period missing meal data where
it is highly likely that a meal or two was eaten during this time, shown by the
two peaks of modelled glucose input. This conclusionappeals to common sense,
which dictates that no patient that had been eating regular meals would refuse
food for a period of 34 hours and then resume regular eating habits the next day.
The presence of two insulin administrations during this period also support this
theory.
The second discrepancy lies in the slightly elevated levels of tted glucose
input when compared to modelled meal intakes. Because the level of elevation
is reasonably constant, and is maintained between meals, it likely reects an
elevated level of EGP. This elevation is likely caused by slightly excessive levels
over normal of the increased physiological stress and catecholamine activity that
is typical after cardiac surgery.
The nal unexpected peak in modelled glucose for Patient 7 appears at the
end of the data collection period. Data for one breakfast meal of 35.2g of CHO
was available for this patient, but the time of consumption and some quantities
consumed were ommitted so this meal was left out of the data set. However, the
time of the unknown glucose input does not correspond to a breakfast meal and
it is therefore likely that this meal was consumed at the end of the data collection
period, where there is a nal unexpected peak in modelled glucose intake appears.
3.2 Ambulatory Diabetic Patient Data
Due to the limited patient turnover in the CTW alternative soures of relevant
glycaemic control data were utilised. Ambulatory diabetic individuals present
many similar characteristics of CTW patients and a cohort of such patients was
already available from the research of Wong et al (?). Additionally, data from the
Automated Insulin Dosage Advisor (AIDA) online2(Lehmann and Deutsch, 1993)
20 CHAPTER 3 COHORT DATA
Figure 3.2 Fitted SI prole of Patient 7 with error correction using tted glucose intake
test cases was utilised and considered part of the ambulatory diabetic patient
group. Both sets of patients exhibit signicant diurnal rhythms. However, it is
unknown whether CTW patients exhibit similar rhythms.
Ambulatory diabetics frequently encounter problems with glycaemic control,
particularly in response to the variable nature of meals and exercise. In the
CTW setting, sustained exercise is not encountered, but the problems with post-
prandial glycaemic control are very similar, as is the overall physiological stress.
Patients in the CTW are also sometimes newly diagnosed with Type II diabetes,
which is identied or highlighted by hyperglycaemia seen during their hospital
stay. In other cases, it is possible that glycaemic control problems are early
warning signs of the onset of Type II diabetes or simply caused by the stress
of their condition. In either case, the cohort of ambulatory diabetic patients
provides additional hours of clinical data relevant to glycaemic control of less
acutely ill patients. For much of this research, the ambulatory diabetic cohort is
considered independently of the CTW cohort to detect any signicant variances
in behaviour or characteristics. In the absence of signicant variance, the chorts
can be considered simultaneously in developing tools for a more general ward
cohort.
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3.2.1 Cohort Statistics
A summary of the cohort statistics is shown in Table 3.4. The overall data
illustrates a hyperglycaemic cohort. In particular, the 20.6% over 10 mmol L 1
indicate a signicant level of variability in control.
Median Blood Glucose during stay (mmol L 1) 6.9
Blood Glucose interquartile range (mmol L 1) 5.0-9.4
BG readings below 4 mmol L 1 (%) 12.6
BG readings above 6 mmol L 1 (%) 61.7
BG readings above 7 mmol L 1 (%) 47.9
BG readings above 7.75 mmol L 1 (%) 40.9
BG readings above 10 mmol L 1 (%) 20.6
Table 3.4 Summary statistics of ambulatory diabetic patient data
3.3 ICU Patient Data
Extensive glycaemic conrol data for 394 patients admitted to Christchurch Hos-
pital ICU between 2001 and 2007 is available for this study. Much of this data
is from patients that were placed on the SPRINT protocol between 2005 and
2007. All glucose readings in these patients were taken using a GlucocardTM
test strip. Enteral nutrition consisted primarily of Diabetic Resource, although
Glucerna, Jevity, NovoSource and several other feed types were used at various
times throughout the study. The common use of enteral feeds in the ICU gives
easily quantiable CHO intake values, reducing the overall error in the insulin
sensitivity ts.
However, enteral nutrition is rarely encountered in the wards and thus this
data provides little insight into the characteristics of meal metabolism and gly-
caemic management. Similarly, the heightened degree of illness in ICU patients
compared with the ward patients means that overall metabolism and insulin sen-
sitivity proles are likely to vary signicantly, as would the underlying causes of
hyperglycaemia. For these reasons, a general ICU cohort is not applicable to a
study of glycaemic control in the wards.
Given these points, the transition of ICU patients from a critically ill state
to a less acute state that leads to admission to a ward is of particular interest.
This transition frequently coincides with less exogenous insulin dependence due
to a reduction in stress-induced endogenous glucose production and increasing
endogenous insulin production. Therefore, patients require a less intensive in-
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sulin regime. The mechanics of making this transition safely have been largely
neglected within most hospitals. To examine the patient characteristics found
during this transition period, the last 36 hours data of of all ICU patients dis-
charged to a ward are examined, which consisted of 131 patients from the original
SPRINT cohort of 394. These 36 hours of data could represent the last 36 hours
in the ICU or the last 36 hours of insulin administration in the ICU. Of this
group, 87% of the data included patients still recieving enteral nutrition. The
remaining 13% of patient hours had no meal data available.
Also of interest from this 394 patient cohort is the use of insulin sensitivity
metrics to identify sepsis. In order to correlate hour by hour SI proles to a
patient's sepsis status, further clinical data was required. The collection of this
additional clinical data was very time consuming and thus only conducted on
36 patients that were identied by experienced clinical sta and blood culture
results as having had sepsis during their ICU stay. These patients were also
selected from the 394 patient cohort and thus all had sucient glycaemic control
data density to provide good insulin sensitivity ts. In addition to the existing
glycaemic control data, extensive hour-by-hour clinical data of the sepsis cohort
was gathered. This data had information on the following:
 Heart rate
 Blood pressure
 Respiration rate
 Temperature
 FiO2
 Fluid balance
 Glasgow Coma Scale (GCS) score
Aditionallly, any atrial brilation was noted, as well as the use of any of the
following drugs:
 Antibiotics
 Vasopressin
 Adrenaline
 Noradrenaline
 Dobutamine
From this information, conclusions about the specic times of sepsis can be
drawn.
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3.3.1 Cohort Statistics
The statistics for the nal 36 hours of the stable ICU cohort is shown in Table 3.5.
It is likely that this ICU cohort underestimates the presence of hyperglycaemia
due to the majority of the cohort being on the SPRINT protocol during their
ICU stay. However, the insulin sensitivity proles are still likely to reect a
broadly similar metabolic status to those patients entering the CTW, particularly
in the situation where glycaemic control protocols are in use before admission (eg.
during surgery, ICU patients transitioning to the less acute wards).
Sex (% male) 74.7
Mean age (years) 58.9
Mean APACHE II
Median length of SPRINT use
Median Blood Glucose during stay (mmol L 1) 5.8
Blood Glucose interquartile range (mmol L 1) 5.1-6.6
BG readings below 4 mmol L 1 (%) 3.0
BG readings above 6 mmol L 1 (%) 40.5
BG readings above 7 mmol L 1 (%) 15.2
BG readings above 7.75 mmol L 1 (%) 7.8
BG readings above 10 mmol L 1 (%) 1.7
Table 3.5 Cohort Statistics for the ICU patients included in this study
The statistics for the 36 patient sepsis subcohort is shown in Table 3.6. This
data set also indicates a tightly controlled cohort. However, it is also more
hyperglycaemic than the cohort of Table 3.5, as might be expected.
Sex (% male)
Mean age (years)
Mean APACHE II
Median length of SPRINT use 101
Median Blood Glucose during stay (mmol L 1) 6.0
Blood Glucose interquartile range (mmol L 1) 5.3-6.8
BG readings below 4 mmol L 1 (%) 2.4
BG readings above 6 mmol L 1 (%) 49.3
BG readings above 7 mmol L 1 (%) 20.1
BG readings above 7.75 mmol L 1 (%) 10.9
BG readings above 10 mmol L 1 (%) 2.1
Table 3.6 Cohort statistics for patients potentially having experienced sepsis

Chapter 4
Modelling and Parameter Identication
4.1 Model Structure
The nal form of the model used is given in Equations 4.1-4.5. In Equation 4.3,
X is given the value found by Equation 2.6 in the subcutaneous insulin model
described in Section 2.5.2. A description of all other parameters and a discussion
of their numerical determination is included in Section 4.2.
_GT =  pGGT  
SIGTQ
1 + GQ
+ P (t) + EGP (4.1)
_Q = kI   kQ (4.2)
_I =
 nI
1 + II
+
k2X
Vi
+
u(t)
Vi
+
IB
Vi
(4.3)
_S = k3S + uCHO(t) (4.4)
_T = min(k4T; amax) + k5S (4.5)
P (t) =
min(k4T; amax)
Vp
(4.6)
Where:
GT is blood glucose [mmol L
 1]
pG is endogenous glucose clearance [min
 1]
SI is insulin sensitivity [L mU
 1 min 1]
Q is utilised insulin [mU]
G is the Michaelis-Menton constant for insulin mediated glucose clearance
[L mU 1]
P (t) is plasma glucose input [mmol L 1 min 1]
EGP is endogenous glucose production [mmol L 1 min 1]
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k is the eective life of insulin [min 1]
I is plasma insulin [mU]
n is the insulin decay rate from the plasma [min 1]
I is the Michaelis Menton constant for plasma insulin clearance [L mU
 1]
k2 is the rate of transport of insulin from the intersitium into plasma [min
 1]
X is insulin from the interstitium [mU min 1]
u(t) is the exogenous insulin inputs [mU min 1]
Vi is the distribution volume of insulin [L]
IB is endogenous insulin secretion [mU min
 1]
S is the CHO content of the stomach [g]
T is the CHO content of the ileum [g]
uCHO is the CHO content of meals consumed [g min
 1]
k3 is the CHO gastric emptying rate [min
 1]
k4 is the CHO gut absorption rate [min
 1]
amax is the maximum gut CHO absorption rate [g min
 1]
Vp is glucose plasma distribution volume [L]
4.2 Parameter Values
The minimal model proposed by Bergman et al. (1979, 1981, 1987) describes the
dominant eects in glucose-insulin kinetics. This model has since been modied
to suit the particular characteristics of dierent populations (Bergman, 2005).
The study of critically ill patients in Christchurch Hospital's ICU from 2001-
2008 used the model described in Section 2.5.1 by Equations 2.1 - 2.5. The
primary driving factor identied in such patients is the insulin sensitivity which
is proportional to feed
glucose insulin
when glucose is at a steady state.
4.2.1 Insulin Sensitivity
Insulin sensitivity is a lumped parameter describing the combined eects of in-
sulin on glucose uptake, which is the primary function of insulin. Under normal
physiological functioning, the presence of insulin stimulates the cell walls enabling
glucose to pass through to be processed by mitochondria. When the eect of in-
sulin is diminished, a patient is said to be insulin resistant, which is equivalent
to a low insulin sensitivity.
Insulin sensitivity has been shown to vary signicantly throughout the day
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and during the course of illness (Wilinska et al., 2003; Langouche et al., 2007). It
is the driving parameter behind glucose changes and thus likely to be the key to
achieving good glycaemic control. SI is tted as a piecewise constant parameter,
varying hourly. It is limited to values of 110 5 and 610 3 L mU 1 min 1,
which extends signicantly higher than most reported ranges (Bettini et al., 1995;
Doran, 2004), but as will be demonstrated in Section ??, the modelled value does
not typically extend beyond 210 3 L mU 1 min 1, which is within the range
reported by McDonald et al. (2000).
4.2.2 Endogenous Glucose Production
In order to more accurately capture the true time varying proles of insulin
sensitivity in a critically ill patient the model given in Equations 2.1-2.3 were
modied to include an endogenous glucose production (EGP) term, Equation 2.1
is thus replaced by Equation 4.1 of the ICU model in Section 2.5.1.
The use of the EGP term allows the removal of the GE term to give glucose
dynamics, where GT = G + GE. These changes allow for greater accuracy in
determining SI proles by eliminating the use of equilibrium glucose which is
unknown and must therefore be estimated by statistical means. The GE term
was best estimated by a 12-hourly average of G, which allows some uptake of
insulin sensitivity dynamics into this term, which would be particularly true in
patients exhibiting diurnal cycles such as ambulatory diabetics or less critically ill
patients. By eliminating this periodic re-estimation, the insulin sensitivity found
by the model will more accurately represent true patient dynamics and is also
more physiologically accurate than GE.
EGP is held at a constant 3 mg min 1, which is within the reported range
(Chambrier et al., 2000; Mittelman et al., 1997; Singhal et al., 2002; Dalla Man
et al., 2007). It is at the higher end of the range found by Chambrier et al. (2000)
for both septic and control patients, but the standard deviation was much higher
in septic patients than the control and consequently no statistically signicant
dierence between the groups was observed. Thus, EGP is considered constant
for all patients, whether or not they had sepsis. The value of 3 mg min 1 was
selected to provide minimum time of modelled SI on imposed upper or lower
limits.
It should be noted that the physiological EGP rate has high interpatient vari-
ability and depends on a variety of factors, such as physiological stress, nutrition
levels and glucose levels. The eect of stress is likely to be minimal as all pa-
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tients in each cohort is under similar levels of physiological stress, however, with
ambulatory diabetic patients, such stress levels could vary signicantly during
the course of a day as well as from patient to patient. However, a varying EGP
rate would mathematically uptake SI variation and so a constant rate for each
patient must be chosen. Similarly, when patients consuming regular meals are
considered, it is likely that EGP would be supressed immediately following meal
consumption which usually induce periods of elevated glucose levels due to the
diabetic nature of the chort. However, this eect is not modelled and thus it
is possible that insulin secretion will be overestimated during such periods, or
insulin sensitivity may be overestimated during such periods.
4.2.3 Central Nervous System Uptake
The central nervous system is biologically insulated from low blood glucose levels
since, unlike other cells in the body, insulin is not needed for glucose uptake.
This allows a constant uptake of glucose into the cells of the CNS essentially
regardless of glucose levels in the blood. The only exception to this is extreme
hypoglycaemic incidents (below approximately 2 mmol L 1) at which point the
patient experiences dizziness and loss of consciousness (Guyton and Hall, 2000).
The physical symptoms of such lowered glucose levels can reduce with repeated
exposures to such glycaemic levels, however the ultimate outcome of death is still
death if the hypoglycaemia is left untreated. The changes in glucose metabolism
during such severe hypoglycaemic incidents is, however, beyond the scope of this
research and thus CNS uptake is considered to have a constant eect on glucose
levels over time.
Since CNS glucose uptake is not insulin mediated it cannot be included in the
systemic uptake term in Equation 4.1. It has the mathematical eect of reducing
the EGP of the body, although this should not be mistaken for a physiological
eect. However, for purposes of this study, the EGP term is considered to denote
the overall eect of non-glucose dependent parameters on change in blood glucose.
4.2.4 Glucose Clearance
The rate of glucose clearance from the plasma by non-insulin stimulated means
is modelled by the use of a lumped fractional clearance rate, pG. This term
originates from the original 3-compartment model of Bergman 1981. Studies
suggest that the eect of variability in pG over time is minimal in comparison
to SI . For this reason, pG is considered a constant over time for each patient,
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although interpatient variability is allowed for in the CTW cohort. The nal pG
values are limited between 0.002 and 0.02 min 1, which largely covers the range
found in clinical studies (Avogaro et al., 1989; Bergman et al., 1981; Bettini et al.,
1995; Cobelli et al., 1999; Furler et al., 1985; McDonald et al., 2000; Pillonetto
et al., 2002; ?).
4.2.5 Endogenous Insulin Secretion
In moving focus from critically ill ICU patients to the less acute wards such as
the CTW, endogenous insulin secretion(EIS) becomes a more prominent feature.
This is evidenced by post-prandial peaks in insulin sensitivity when tted using
the model described in Equations 2.1-2.3. An example of such a t is shown in
Figure 4.1. The majority of meal inputs, as shown in the P (t) curve induces a
peak in insulin sensitivity for between 1-4 hours after the initial carbohydrate
input.
Figure 4.1 An example of a patients SI prole compared to modelled glucose intake with no
endogenous insulin secretion
Since SI is tted hourly, it is likely that this compensation for EIS misses
the rst peak phase of insulin secretion which usually last for approximately
10 minutes before reducing and then re-elevating for 2-3 hours following a meal
(Guyton and Hall, 2000; Pratley and Weyer, 2001). However, it is also possible
that this rst phase secretion is absent due to the impairment of beta cell response
inherent in the nature of diabetes. A comparison between a healthy post-prandial
insulin response and that of a patient with Type II diabetes is shown in Figure
4.2. Note that a patient with Type I diabetes would exhibit negligible levels of
insulin.
An upper limit of endogenous insulin secretion is imposed to maintain phys-
iological accuracy. A limit of 10 U hr 1 is imposed on all insulin secretion rates.
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Figure 4.2 A qualitative comparison between the endogenous insulin secretion proles of a
healthy patient and one with Type II diabetes in response to a meal. Note that the rst phase
response of a healthy patient is completely missed by the patient with Type II diabetes.
This value lies on the upper range for of insulin secretion rates in obese pa-
tients derived from a two-compartment model based on C-peptide measurements
(Polonsky et al., 1988) and is almost twice that found by a study in healthy
subjects during glucose infusion(Porksen et al., 1997). While not all patients in
the cohort are obese, it is likely that some will fall into this category, thus it is
necessary that the upper limit allows for this. At all other times, basal insulin
secretion is considered negligible.
Hyperglycaemia in the CTW was more commonly observed in patients with
a history of diabetes and it is therefore likely that the cause is in failure of
natural glucose control systems exacerbated by stress than solely stress-induced
hyperglycaemia. Coupled with the lower insulin doses encountered in the CTW,
this implies that insulin secretion is likely to be less signicantly suppressed in
such patients.
Modelling the arrival of endogenous insulin secretions (EIS) into the plasma
allows basal replacement therapy to be modelled where the reduced endogenous
function is allowed to manage post-prandial glucose rises. Basal replacement
therapy for Type II diabetics has been investigated as a control strategy by
numerous studies as summarised in Section 2.2.
It is well documented that exogenous insulin suppresses the secretion of en-
dogenous insulin. This was taken into account by the e u(t) factor of IB in the
ICU model, where IB was assumed constant. However, the supression of EIS is
assumed to be complete at all times except for 3 hours after a meal. It is as-
sumed that after meals, EIS in a Type II diabetic is not suppressed by exogenous
insulin in any levels that would be encountered in a practical situation. If EIS
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is not suppressed to the extent assumed, the eect would be overestimation of
insulin inputs, which would result in higher glucose levels than desired. However,
underestimating IB could result in an insulin overdose, causing hypoglycaemic
events. Therefore, the inclusion of EIS in initial pilot trials is the safest option
and accounting for EIS suppression might be developed after initial clinical trials.
It is important to note that the secretion rates calculated are the rates of
secreted insulin that arrives in the plasma, not the rate of secretion by the -cells.
Approximately 50% of the insulin secreted by -cells is cleared by the liver before
taking eect on cellular glucose uptake. However, the aim of this research is to
accurately model the dynamics between glucose and exogenous insulin rather than
endogenous insulin dynamics and therefore the exact values rate insulin secretion
and extraction are not required and would simply add unnecessary complexity to
the model.
4.2.6 Subcutaneous Insulin
Wong et al. (2008); Wong (2008) modelled the eect of various types of insulin
used in ambulatory diabetic patient management. While only IV insulin and
insulin glargine are investigated for use in this study, much of the data available
is from patients using a wide variety of insulin types. Thus the arrival of these
insulins into the plasma needs to be modelled. This is achieved by the use of a
subcutaneous insulin model described in Section 2.5.2.
4.3 Parameter Identication
4.3.1 Population Constants
The value of all population constants used are given in Table 4.3.1.
4.3.2 Fitted Parameters
Both insulin sensitivity (SI) and endogenous insulin secretion (IB) are considered
variables in this model and thus both parameters must be tted. Insulin sensi-
tivity is assumed piecewise constant over each hour, whereas insulin secretion
is constant over 10 minute periods. The model given in Section 4.1, which is
used for the CTW patients thus includes a nonlinear term, SIGtQeff in Equation
4.1, to the system to be solved. Nonlinear solution methods present a signicant
computational burden, which reduces the available number of paitient hours that
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Parameter Value
G 0.015 L mU
 1
I 0.0017 L mU
 1
EGP 1.16 mmol L 1 min 1
n 0.16 min 1
k 0.0099 min 1
k2 0.0649 min
 1
k3 0.0388 min
 1
k4 0.0097 min
 1
amax 1.1
Vp 22% of bodymass
Vi 15% of bodymass
Table 4.1 Constant model parameters used
can be considered. Therefore, the tting is not solved as a simultaneous system,
but rather as a sequential series of SI proles, with Qeff resolved for 3 hours
following the meal periods, assuming a constant SI . It has been shown (Wilinska
et al., 2004; la Fleur, 2003; la Fleur et al., 2001) that insulin sensitivity varies
signicantly over a day and therefore it is not expected that insulin sensitivity
would remain constant over the 3 hours following a meal. However, a constant
SI is required to identify endogenous insulin secretion.
Data is divided into periods for tting, where each period goes from 3 hours
following the last meal (or the rst available data point) up to 3 hours following
the next meal. If another meal is eaten within the nal three hours, then SI
becomes variable again 3 hours following the last meal. Once each section has
been solved, SI is retted over the whole time period to correct any error which
arises from needing negative IB values, which are not physiologically possible.
Integrating Equation 4.1 over a time period gives:
Z t+x
t
_Gdt = Gt+x  Gt =  pG
Z t+x
t
Gdt  SI
Z t+x
t
GQdt+
Z t+x
t
P (t) + EGP
V
dt(4.7)
In Equation 4.7, x is 10 when SI is being tted and 1 when IB is being tted.
Thus, there are 6 and equations for SI and IB respectively when solving the
system, which is of the form: [A]
0
@ SI
Q
1
A = b. Such a system can be solved by
the method of least squares.
Once the system has been solved, (t)Q(t) can be found since SI;tn 3 is known.
Dierentiating the last 18 elements of the solution vector then gives the GQ
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product over time and thus Qeff (and hence Q) can be found. From known
Q the _Q equation can be integrated written in terms of
R
Idt using the same
method as above. The integrated Equation 4.2 is given in Equation 4.8. From
this equation, a system of the form [k] (~I) = Q can be written and solved.
Z t+1
t
_Qdt = Qt+1  Qt =  k
Z t+1
t
Qdt+ k
Z t+1
t
Idt (4.8)
Finally, from this solution,
R
IBdt can be tted to the _I equation using known
insulin inputs. Equation 4.3 is shown in its integrated form in Equation ??. The
solution to the resulting system is the desired 18 1 solution vector of endogenous
insulin secretion. The linear least squares solution for IB is bound to be positive.
Z t+1
t
_Idt = It+1   It =  n
Z t+1
t
I
1 + II
dt+
1
V
Z t+1
t
u(t)dt+
1
V
Z t+1
t
IBdt (4.9)
The t values of IB should approximate the expected prole of insulin secre-
tion, shown in Figure 4.2. It is possible to t a curve through these secretion
rates found to reect this prole and use this curve for the insulin secretion model,
however due to the small changes in rate that occur over 10 minutes, with the
occasional exception of an acute spike in the initial stage, it is likely that this
would not aect the accuracy of the ts obtained.
An example of a patient tted using this method is shown in Figure 4.3. The
shaded regions indicate time during which SI is held constant and IB is tted.
It can be seen that the period of IB tting is sometimes longer than three hours,
which occurs when a patient consumes a meal within 3 hours of the last. In this
case, SI is held constant for the duration of the meals and becomes variable again
3 hours after the nal meal.
An extensive validation study of this model is yet to be carried out. C-
peptide data would need to be available to conrm the EIS rates tted using the
methods described above. Similarly, continued data collection in relevant patient
cohorts will assist in validating the model, particularly if insulin is administered
throughout the patients stay.
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Figure 4.3 Fitted and modelled data for CTW patient 5
Chapter 5
Stochastic Modelling
The improvement of glycaemic control with increased measurement and inter-
vention adjustment frequency is well established. However, in many settings,
the increased burden on clinical sta introduced by such glycaemic control pro-
tocols is restrictive (Mackenzie et al., 2005; Aragon, 2006). Thus, minimising
the frequency of adjustment or measurement in glucose control strategies is of
paramount importance to attain maximum eectiveness for minimal impact on
clinical burden. In this chapter, stochastic modelling methods are employed to
generate a virtual patient cohort that reects the physiology of patients encoun-
tered in less acute wards with lower nurse:patient ratios. These proles can then
be used in control utilizing 1-3 hourly measurements to optimize clinical burden
in the overall result.
5.1 Methodology
To predict the eect of a treatment protocol on a population, understanding
insulin-glucose dynamics alone is insucient. Time varying proles of patient
specic parameters are required to simulate how any therapies interact with
these progressions over time. However, to achieve good correspondence between
simulation and clinical results many hundreds of hours of clinical data are re-
quired, which takes time and resources to collect. Stochastic modelling enables
understanding of population characteristics as a probabilistic model using Markov
chains.
It is physiologically expected and well recorded that current insulin sensitivity
of a patient is related to insulin sensitivity after one hour. Given that future
insulin sensitivity can be viewed as a conditional progression from a present
insulin sensitivity state, it can be modelled using Markov chains. Lin (2007)
developed a stochastic model of insulin sensitivities of critically ill patients using
36 CHAPTER 5 STOCHASTIC MODELLING
a cohort of 394 ICU patients from Christchurch Hospital using 2-dimensional
kernel density estimation.
Such predictive measures reduce the heightened risk of hypoglycaemic episodes
in patients recieving intensive insulin therapy (Chase et al., 2007). The model
is dened by condence bands based on clinically observed parameter variations.
Using Monte Carlo methods, statistically accurate SI proles can be generated,
thus creating a 'Virtual Patient'. Validation against 23,324 hours of clinical
SPRINT data has shown an excellent correspondence in control algorithm re-
sults on Virtual Patients (Lin et al., 2008; Chase et al., 2007).
The probabilistic model generated will determine the most likely insulin sen-
sitivity to follow a given present value for a subset of patients. The probability of
each outcome for a given present value is determined by the tted clinical data.
It is assumed that insulin sensitivity is dependent only on its previous hourly
value. Clinically, this assumption holds true because patients generally experi-
ence changes in their metabolism that are caused by unmodelled external factors,
such as a worsening of the admission condition. However, there is evidence that
insulin sensitivity generally progresses during a patients stay (Langouche et al.,
2007).
This should not aect the validity of the Markovian assumption for the appli-
cation of the model to the control problem since it is not trends over long periods
of time that aect a patient's need for insulin or glucose, but rather over 2-3 hour
periods. The control inputs need to be able to respond to the higher frequency
changes in insulin sensitivity. However, if data included long periods of stay, the
Markovian property assumption may become invalid.
Two dimensional kernel density estimation of SI is generated from the data
described in Section 5.2. The conditional probability of each outcome is calcu-
lated by the probability of the sequence of data as determined by the observed
frequency in clinical data and normalised by the probability of the initial condi-
tion. Since SI values are continuous a discretisation must be made to calculate
these probabilities. For the models presented in this thesis, SI is discretised with
a resolution of 610 5 L mU 1 min 1. The probability density function is such
that the integral of the probability curve between 1  10 6 and 6  10 3 L mU 1
min 1 is equal to one. Thus, a slice along the SI;t-axis of the generated density
functions gives the distribution of likelihood of the subsequent SI reading for a
given current SI . The joint probability density function is weighted by the prob-
ability of SI;t = x so that the most likely SI values have highest density values.
The normalisation is such that the integral of the surface is equal to one.
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5.2 Probability Model
Using the methods of Lin et al. (2006, 2008) as described in Section 2.5.4, a two
dimensional kernel estimation function was generated using the subset of 394
patients admitted to the Christchurch Hospital ICU during the years 2001-2007
and experienced hyperglycaemia during their ICU stay. Details of this subset are
given in Section 3.3. Patients from this cohort were chosen to isolate more stable
ICU patients which would closely resemble the characteristics of a patient found
in the CTW. This was achieved by selecting patients that were discharged to the
ward and examining the last 36 hours of their ICU stay. In total, 4104 hours
of patient data pairs were available for the model generation, collected from 130
patients of the 394 cohort. The dierence between the expected number of hours
(130 patients  36 hours) is due to some of the 130 patient stays being shorter
than 36 hours, or at least the period of glycaemic data available did not exceed
36 hours.
It is expected that the glycaemic control data of ward patients is fundamen-
tally dierent to that of ICU patients. ICU patients are more critically ill and
recieve larger doses of insulin which is entirely intravenous (IV). However, it is
not uncommon for patients to recieve IV insulin as part of the SPRINT protocol
and need to transition to subcutaneous insulin. This transition needs to be ex-
amined also. For this purpose, the last 36 hours of ICU patient data of patients
discharged to a ward following their ICU stay were examined. This is the period
most closely resembling the physiological characteristics of a patient in the ward,
although nutrition and insulin therapies will be signicantly dierent once a pa-
tient is in the ward. These dierences necessitate the use of additional insulin
compartments to describe the action of the range of insulin therapies encountered.
All of these patients were on the SPRINT protocol during the stable period
that was isolated and 87% of patients were on the SPRINT protocol for insulin
administration alone. That is, 13% of patient hours considered were collected
from patients consuming regular, unregulated meals, which is also a characteristic
of patients in the CTW. However, data on the meals consumed is not available
and thus no compensatory measures such as endogenous insulin secretion spikes
are considered.
The insulin sensitivity pair distribution is shown in Figure 5.1 along with
the condence intervals. The probability densities generated for this cohort of
data are shown in Figure 5.2 and Figure 5.3. The density of data available for
insulin sensitivities greater than 3  10 3 mU L 1 min 1 is very low as shown in
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Figure 5.1. Therefore, there is poor model quality for insulin sensitivities greater
than this, expressed as an irregular and highly asymmetric surface. Overall,
the amount of data available is likely insucient to generate a model which will
accurately represent the characteristics of a patient in the CTW, as would be
expected from the results of Lin et al. (2008, 2006) which observed convergence
after 1200 patient hours with a smaller domain of possible SI values.
Figure 5.1 Condence intervals for SI;t+1 values for stable ICU cohort
The SI data used in the model creation uses 3 point smoothing, however in
order to maintain clinical applicability the smoothing was done using the last
3 SI values rather than using future values, as would normally be done. This
type of smoothing has the potential to introduce a lag in a controller's response
to changes in glucose levels, but would also prevent a controller overreacting to
a spike in percieved SI reading due to a contaminated sample or similar error.
This type of retrospective smoothing could be easily implemented into a clinical
setting and therefore the use of smoothing does not adversely aect the useability
of the results. Smoothing has the eect of tightening the probability distribu-
tions towards the line SI;t = SI;t+1 as can be seen in comparing (a) and (b) of
Figure 5.2. The high frequency noise that is removed by smoothing is unlikely to
be physiologically accurate as variation in SI has been shown to vary diurnally
(la Fleur, 2003; la Fleur et al., 2001).
5.2 PROBABILITY MODEL 39
Figure 5.2 Probability density function for ICU patients
Figure 5.3 Joint probability density function for ICU patients
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(a) No smoothing (b) 3 point smoothing
Figure 5.4 The eect of smoothing on lower section of insulin sensitivity distributions
5.2.1 Validation
5.2.1.1 Data Inclusion
Table 5.1 shows the model for the same patients, but using increased or decreased
periods of data inclusion. Comparing the data between these groups shows that
the period of inclusion does not signicantly aect the model developed for ran-
dom sample sets of 1000 values. The p-values for Table 5.1 are calculated using
the Kolmogorov-Smirnov test, which compares the two sample sets and tests the
hypothesis that the data values are drawn from the same distribution. Thus, the
results indicate the desired similarity in this case.
Hours prior to discharge Hours of Data P-value*
12 1577 0.78
24 2919 0.43
36 4104 0.85
48 5224 -
*P values comparing the distribution from 48 hours of inclusion
to the stated number of hours inclusion
Table 5.1 Comparison of insulin sensitivity distributions for varying hours prior to discharge
included
There is a high density of readings at the imposed lower limits of SI in the
ICU cohort. The lower limit of SI (110
 6 L mU 1 min 1) is frequently found
during periods of time when a patient is given no insulin. If patients with a
period of more than 6 hours without insulin are excluded from the model, the
probability distributions show lower densities at these limiting values, as can
be seen by comparing Figures 5.1 and 5.5. However, increased asymmetry and
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irregularities increase due to the reduced quantity of data available, particularly
at SI above 2 10
 3 L mU 1 min 1.
Figure 5.5 Condence intervals for SI;t+1 values for stable ICU cohort, excluding periods
without insulin dosing
5.2.1.2 Random Walk compared to Clinical Data
To test the validity of assumption of SI as a Markov variable, the results from a
random walk of 2 and 3 hours is compared to the condence intervals expected
from clinical data. The results of this analysis are shown in Table 5.2. Table 5.2
indicates that while the 90% condence interval gives a good bound on the clinical
data, the model signicantly overestimates the variability in the 50% condence
interval creating a narrower peaked distribution. The key aspect is that the data
distribution on either side of the median remains relatively constant. A large
trend to one side would indicate time dependent directed progression of clinical
data that is unmodelled in this case. There is a large change in the 50% condence
interval at 2 hour predictions, but as all other elements are largely equal, it is
likely the result of some set of outliers in the data.
5.2.1.3 Comparison to other data
In addition to the ICU patient data, the 7 CTW patient tted proles were
examined. This time of hourly varying SI constituted 88.4% of patient time over
the given cohort. For the remaining 11.6% of patient time, EIS was tted and
SI held constant. Variance in SI during this time is considered after IB has
42 CHAPTER 5 STOCHASTIC MODELLING
1 hour 2 hours 3 hours
50% Condence Interval 62.2% 68.2% 62.6%
90% Condence Interval 91.8% 91.0% 89.7%
Number of Patients Above 50th percentile 57.1% 50.9% 51.5%
Number of Patients Below 50th percentile 42.9% 48.1% 48.5%
Table 5.2 Proportion of clinical ICU SI;t and SI;t+2;3 pairs falling between model generated
from a 2 and 3 hour random walk
been tted and therefore these periods are thus still able to be included in the
stochastic model. To omit the SI values during this time would bias the model
towards times during which meals are not eaten.
Finally, data from 10 Ambulatory Diabetic patients was utilized to compare
SI distributions. It is expected that these patients will exhibit higher SI values
than the CTW or ICU patients because they are otherwise healthy subjects.
However, this data provides a comparison to ensure that the modied tting
method employed on CTW patients is not causing any signicant changes between
the groups.
A comparison of the stochastic model generated to a similar model generated
by the limited amount of clinical data specic to the problem is summarised
below. The clinical data is then compared to the stochastic model created and
the results are shown in Table 5.3.
1 hour 2 hours 3 hours
50% Condence Interval 47.9% 49.8% 45.2%
90% Condence Interval 79.4% 81.4% 78.2%
Table 5.3 Incidence of SI;t and SI;t+1 pairs from CTW patients within ICU patient condence
intervals
Figures 5.6-5.7 shows the distribution of SI;t+1 for each group. In all cases,
Lin et al. (2006, 2008) found that with approximately 1200 patient hours of data,
model convergence was observed, when compared with a similar model from
23,000 patient hours. However, the range of possible SI readings was limited
from 1  10 5 L mU 1 min 1 to 1:2  10 3 L mU 1 min 1 and in the models
generated for the CTW and ambulatory cohorts, the model uses an increased
range of 110 5 L mU 1 min 1 to 6 10 3 L mU 1 min 1. It is therefore likely
that more data will be required to obtain an equally reliable model.
Figures 5.6 and 5.7 show the condence intervals for available data from the
CTW and ambulatory diabetic patients respectively. However, in both cases, the
5.2 PROBABILITY MODEL 43
Figure 5.6 Condence intervals for SI;t+1 values for CTW cohort
number of hours available is low (600 hours combined) compared to that for the
ICU cohort model (over 4000). Hence, its reliability may be less and variability
greater.
It is clear that there is a greater relative density of low SI in the CTW cohort
than the ICU patients, likely due to the presence of diabetes in all patients
included in the study. The CTW patients showed greater density of data in
the higher SI range than the ambulatory diabetics. This result is likely because
the CTW cohort has a subset of diabetic patients, but also includes patients
experiencing glycaemic control problems without any previous history of diabetes.
Therefore, it is possible that some CTW patients' hyperglycaemia is not due to
insulin resistance, but due to increased stress-related gluconeogenesis brought on
by their condition or surgery. The CTW patients also show signicantly higher
variance, which could be expected due to their changing condition.
5.2.1.4 Model Convergence
To determine if sucient data is available to produce reliable model results a
model convergence study was carried out. The convergence study is conducted on
the stable ICU cohort as it has the greatest amount of data available. Following
the method of Lin 2007, the patients are divided into four equal groups and
a model is built from 3 of the 4 data sets. The remaining data set can then
be compared to the modelled condence intervals and the proportion of data
lying between these bounds can be compared. The statistics for each group are
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Figure 5.7 Condence intervals for SI;t+1 values for Ambulatory Diabetic cohort
summarised in Table 5.4.
The results of the study are summarised in Table 5.5 and there is some sig-
nicant variance between the sets of patients and the nal combined result. This
outcome indicates that additional data may be required for model convergence.
In light of this, it is expected that the CTW model with much less data will
also require further clinical results before a satisfactory stochastic model can be
developed.
Group APACHE II Age Gender LOSa Mean BG
(% Male) (Days) (mmol L 1)*
1 19.7 56.3 73.3 13.6 5.7
2 18.2 60.1 75.1 8.8 6.2
3 20.3 61.5 75.1 11.0 5.2
4 19.8 57.9 74.5 12.2 6.0
a Length of stay
* p < 0.05
Table 5.4 Average statistics for data groups used in convergence study
It is interesting to note that the predicted condence intervals are consistently
conservative, particularly the 50% condence bounds. This behaviour has been
observed by other studies (?Lin et al., 2008, 2006). This result may be due
to the variance estimator employed, and could potentially be corrected by bias-
variance trade-o. Interestingly, the pontentially more useful 90% bounds are
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Percentage of Data Percentage of Data
Excluded Test Group falling between the falling between the
50% condence interval 90% condence interval
1 60.1 91.4
2 57.5 90.2
3 66.5 92.4
4 66.3 94.6
- 61.2 92.1
Table 5.5 Proportion of SI;t+1 values falling between predicted condence bounds in conver-
gence study over 5 test groups
more accurate indicating a mismatch between the clinical data and assumed
distributions.

Chapter 6
Glycaemic Control Protocols
Glycaemic control has been shown to reduce mortality, sepsis and other negative
outcomes in critically ill patients. It has also been recognised as an important
factor in managing diabetes in ambulatory patients. The methods of attaint-
ing normoglycaemia in such a variety of patient parameters and lifestyles have
however proved far more elusive. Lonergan et al. (2006b) produced the paper
based SPRINT protocol for use in critically ill patients, particularly those on en-
teral feed. This protocol increased patient time between 4.4-6.1 mmol L 1 from
30% to 53.9% (?). However, SPRINT requires measurements every 1-2 hours,
which is a large clinical burden. Alternative strategies based on the principle
of SPRINT but employing the use of long-acting insulin or predictive measures
could potentially make tight glycaemic control accessible in a ward setting.
6.1 SPRINT in the Wards
6.1.1 SPRINT with Insulin Infusions
SPRINT is a nearly established protocol in Christchurch Hospital ICU. How-
ever, the ICU has a 1:1 nurse to patient ratio, allowing for the extra burden
that SPRINT places on clinical sta. The frequent blood glucose readings and
insulin/feed adjustments (1-2 hourly) and hourly bolus administrations are likely
to become overly cumbersome within a ward setting where nurse to patient ratios
are closer to 1:3 or worse. Therefore, measurement periods of 1-3 hours are more
likely to achieve practical success in clinical implementation. For this purpose,
insulin infusions are also likely to be better suited. Infusions require less time to
complete protocol related tasks and would likely need adjustment less frequently
once stability is attained. The greatest risk of this approach is that of hypogly-
caemia, which may result from infusions being allowed to run over the specied
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Figure 6.1 The SPRINT insulin wheel
time period.
SPRINT is an adaptive glycaemic control protocol that responds to changes in
glucose (derivative control) by adjusting feed and insulin doses. Because SPRINT
is well established in Christchurch Hospital's ICU a similar control system would
be easier to clinically implement in the wards than other novel approaches. CTW
patients are not enterally fed and thus all nutrition comes from meals consumed
at irregular intervals over the course of a day, followed by nightime fasting. Sim-
ulations were run on CTW and ambulatory diabetic patients using the SPRINT
insulin wheel only (see Figure 6.1) to determine IV insulin infusions. Meals were
not modied or controlled in any way, as would be expected in a clinical setting.
The simulations showed very poor glycaemic control with a very high inci-
dence of hypoglycaemia. These results are potentially dangerous and unaccept-
able for clinical practice. The summary statistics for the response of the cohort
to this algorithm is shown in Table 6.1.
In particular, hypoglycaemia was common following meals and during long
fasting periods, such as during night. SPRINT was also slow to mitigate the
high blood glucose levels observed following large carbohydrate intakes. These
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results are actually to be expected, as SPRINT was designed for patients receiving
relatively constant glucose inputs and required adjustment of the feed rates based
on glucose levels. Since the glucose intake (in the form of meals) in CTW patients
are more like impulses than constant forces on the system, SPRINT cannot adjust
to the rapid changes in glucose levels and insulin requirements. In addition,
assuming constant nutrition means that it is equally slow to shut o insulin
between irregular CTW meals.
It is not clear if the model employed is overestimating a patients postpran-
dial response to insulin infusions, but highly likely. Insulin sensitivity generally
peaks around meal times, as described in Section 4.2.5. If this eect is not
physiologically real and instead represents a modelling error due to the omission
of endogenous insulin secrection then the hypoglycaemia incidence rate will be
overstated.
To check the extent of this possible modeling error, identical simulations were
run using the modied model described by Equations 4.1-4.3 which include a t-
ted IB. The summary statistics for these simulations are shown in Table 6.1.
It is important to note that the model employed in these simulations has not
undergone validation for the CTW cohort or similar group. Thus, the protocols
proposed below could potentially be underestimating insulin sensitivity during
endogenous insulin secretion. If this is the case, then the response to insulin in-
puts would be much larger than expected and could thus induce a hypoglycaemic
incident.
The inclusion of EIS does mean that a portion of the required insulin to allow
uptake of the glucose input into the cells is provided by the body's physiological
responses to elevated levels. If this portion of insulin recommended is counted as
part of the SPRINT input, then it would help counteract the eects of underesti-
mating insulin sensitivity while using SPRINT, as EIS is the uptake of modeled
insulin sensitivity dynamics when insulin sensitivity is frozen.
6.1.2 Modications to SPRINT
The results of the CTW cohort being controlled by the SPRINT insulin wheel
(Figure 6.1) are summarised in Table 6.1. The results show a high level of hy-
poglycaemia and little success in maintaining blood glucose levels in a desireable
4-7 mmol L  1 band.
The response of SPRINT to changes in blood glucose are agressive in terms
of insulin dose adjustments. SPRINT is able to deliver a high dose of insulin
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in response to blood glucose spikes without signicantly increasing the risk of
hypoglycaemia as feed levels in the ICU can be increased on the next hour if a
large drop of blood glucose is observed. In contrast, in the wards, this response
is not available because of the nature of nutrition recieved by the patient.
Similarly, the Insulin Wheel is not designed to respond to large carbohydrate
intakes that result in blood glucose spikes. A spike in glucose in an ICU patient
represents either an erroneous measurement or a change in patient condition.
Thus, SPRINT needs to respond to this change by adjusting baseline doses grad-
ually until equilibrium is achieved. Clearly this response is not appropriate to
postprandial blood glucose behaviour. To address these issues, several modi-
cations were made to the SPRINT insulin wheel and/or its use, as described
below.
6.1.2.1 Reducing Insulin Dose
SPRINT is generally too aggressive in reducing glucose for CTW cohorts, with
little safeguard against hypoglycaemia as the feed is not modulated. Therefore,
simulations were run that administered the recommended SPRINT dose as an
infusion, less 1 U hr 1. The results of these simulations are shown in Table 6.1
and are compared to the unmodied SPRINT results for the same cohort.
SPRINT SPRINT reduced
by 1 U hr 1
Fit Parameter(s): SI SI and IB SI SI and IB
Time between 4.0-6.1 mmol L 1 37.3% 35.4% 36.8% 33.6%
Time between 4.0-7.0 mmol L 1 47.1% 49.7% 49.2% 46.7%
Time between 4.0-7.75 mmol L 1 54.0% 57.0% 56.2% 56.6%
Time above 6 mmol L 1 39.2% 48.0% 45.3% 52.2%
Time below 4 mmol L 1 24.4% 17.4% 19.2% 15.7%
Time below 2.5 mmol L 1 10.0% 6.6% 6.6% 5.1%
Time below 2.2 mmol L 1 3.5% 1.5% 1.8% 1.3%
Mean Blood Glucose (mmol L 1) 6.2 6.6 6.5 6.8
Standard Deviation (mmol L 1) 3.2 3.2 3.2 3.2
Table 6.1 Simulation results for SPRINT and SPRINT reduced by 1 U hr 1
Table 6.1 clearly indicates that while the incidence of hypoglycaemic episodes
is greatly reduced by reducing the SPRINT infusion, it is at the cost of an in-
crease in hyperglycaemia. It appears that this change merely shifted the glucose
distribution toward the higher blood glucose region, while losing some tightness
of control. This outcome is also illustrated by Figure 6.2.
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Figure 6.2 Blood glucose readings distribution for SPRINT and two modications
6.1.3 Meal Dependent Boluses
Emulating the principles of 'Carb Counting' (Section 2.2), a strategy to include
meal boluses into the SPRINT protocol was investigated. The number of car-
bohydrates consumed in a meal was used as a guide to the IV insulin bolus
administered. The use of similar principles has been investigated by several stud-
ies (Raslov et al., 2004; Perriello et al., 2005; Dailey et al., 2004; ?), although
rapid acting subcutaneous insulins were used instead of IV insulin. Meal boluses
were to be administered to a patient one and sometimes also two hours after
consuming a meal, their size based on the carbohydrate content of what was
eaten and in some cases, the time of the day. Using two meal boluses instead
of one allows for a conservative choice to be made in the rst instance and then
correction of an inadequate bolus at the second, if required, without prolonged
hyperglycaemia. The results for these simulations are given in Tables 6.2 and
Figure ctwvsbolus. A constant 1 U hr 1 IV infusion was present at all times,
except for when glucose levels fell below 5 mmol L 1.
This approach should remedy the problem with slow response to blood glucose
peaks that SPRINT inherently entails. However, because such large doses are
being administered in bolus form, a much higher risk of hypoglycaemia may be
present. While in some cases, boluses deliver good reduction in postprandial
glucose spikes, others reach dangerously low blood glucose rates. It is important
to note that the model employed here is not validated in these low glucose readings
of less than 2 mmol L 1 and thus gures below this value are likely indicative
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Figure 6.3 A comparison between the glucose distributions of CTW clinical data and pre-
dictive control results. Fits assume a lognormal distribution.
only. It is likely that glucose levels this low would cause severe phsyical symptoms,
which would alert clinical sta to the situation. Levels this low should also induce
an increase in EGP, which is not modelled directly due to the high diculty in
quantifying such an eect given inter-patient variability.
Bolus at 1 hr: CHO/8 CHO/16 CHO/32 CHO/32
Bolus at 2 hrs: - - - CHO/64
Time between 4.0-6.1 mmol L 1 34.2% 35.0% 33.6 34.3%
Time between 4.0-7.0 mmol L 1 45.4% 45.3% 44.6 44.8%
Time between 4.0-7.75 mmol L 1 52.6% 53.6% 53.1 53.4%
Time above 6 mmol L 1 45.1% 46.7% 49.3% 46.6%
Time below 4 mmol L 1 22.3% 19.4% 18.8% 20.1%
Time below 2.5 mmol L 1 10.3% 9.2% 8.8% 9.4%
Time below 2.2 mmol L 1 5.8% 5.2% 4.9% 4.6%
Mean Blood Glucose (mmol L 1) 6.3 6.8 6.6 6.5%
Standard Deviation (mmol L 1) 3.9 3.7 3.7 3.6%
Table 6.2 Simulation results for protocols using meal dependent boluses. All dosing ratios
include a constant 1 U hr 1 IV infusion, except for when glucose below 5 mmol L 1 is measured
6.1.4 Basal Insulin Replacement Strategies
Glargine mimics the basal insulin secretion of a healthy pancreas and lasts for
approximately 24 hours. It exhibits no peak action and therefore is not a sub-
stitute for post-prandial insulin secretion, which (if required) must be replaced
6.1 SPRINT IN THE WARDS 53
with a bolus of short acting insulin or with endogenous function. For this rea-
son, glargine administration trials are run only on the insulin sensitivity proles
that include EIS. Glargine has often been used in conjunction with oral hypogly-
caemics and insulin dose is usually adjusted over a period of weeks to ensure good
equilibrium. However, patients in the CTW require targeted glycaemic control
over a period of a few days, so the titration of glargine must be relatively rapid.
Daily glargine dose adjustments for the Treat-to-Target protocol (Riddle
et al., 2003) are given in Table 6.3. All patients start on a 10U dose, which
is then adjusted daily. Meal boluses of CHO
16
are preserved for one simulation.
Simulation results are summarised in Table 6.4 for this approach.
Morning Fasting Glucose Dose Adjustment
(mmol L 1)
 10 +8U
7.8 - 10 +6U
6.7 - 7.8 +4U
5.6 - 6.7 +2U
 5.6 -
Table 6.3 Glargine dose titration for Treat-to-Target protocol
Meal Bolus No Bolus
Time between 4.0-6.1 mmol L 1 37.3% 12.1%
Time between 4.0-7.0 mmol L 1 47.1% 23.4%
Time between 4.0-7.75 mmol L 1 54.0% 33.0%
Time above 6 mmol L 1 39.2% 82.4%
Time below 4 mmol L 1 24.4% 5.9%
Time below 2.5 mmol L 1 10.0% 2.5%
Time below 2.2 mmol L 1 3.5% 1.4%
Mean Blood Glucose (mmol L 1) 8.9
Standard Deviation (mmol L 1) 3.9
Table 6.4 Simulation results for glargine based protocol
The results in Table 6.4 suggest that insulin glargine is not appropriate for
control of CTW patients. While the glucose levels do normalise after several days
of treatment (see Figure 6.4), the initial period sees little to no improvement over
the actual clinical results (shown as a dashed line).
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Figure 6.4 An example of a CTW patient on the Treat-to-Target protocol
6.2 Predictive Control
Predictive control has been used by ?? to eectively control glucose in intensive
care. Similar principles can be applied to less critically ill patients in order to
determine the eectiveness of glycaemic control methods at less frequent mea-
surement and intervention intervals. The model used for prediction is shown in
Figure 5.3. The rst SI value is predicted based on the 50th percentile of the
stochastic model of the appropriate cohort. The second is based on the initial SI
reading, but from the model's 50th percentile after two hours and the same for
the third. Thus, the predictions are all made based on data that is only acquired
every third hour. Thus, the uncertainty grows with time, as seen by the 50% and
90% condence bands. An example of these growing condence bands are shown
in Figure 6.5.
The target to be achieved greatly aects the performance of the controller.
Performance is altered by varying insulin infusions from between 0 and 10 U hr 1
with resolution of 0.5 U hr 1. To prevent unacceptable levels of hypoglycaemia,
a target can be set that keeps the 5th percentile above 4 mmol L 1, however,
when condence bands are large, this necessarily requires a large probability of
hyperglycaemia. Thus, for this study, a target of 5 mmol L 1 or a reduction of
1.5 mmol L 1 hr 1 is set, with no constraints on the lower condence bands.
To examine the eect of measurement frequency, predictive control is run
based on 1,2 or 3 hourly measurements. The glycaemic control results are shown
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Figure 6.5 An example of the growth of condence bands over time. In the blood glucose
graph, the dotted line represents the tted clinical outcome over the time considered. The 50%
and 90% condence bands of blood glucose are shown in dark grey and light grey respectively.
The modelled glucose prole is shown by the solid line. The red lines indicate the ideal blood
glucose range. For the insulin sensitivity graph, the actual tted SI prole is shown in a
solid blue line while the 50% and 90% condence intervals in SI are shown in dark red and
red respectively. The insulin infusion graph indicates the insulin dose administered and the
carbohydrate intake graph indicates the time and carbohydrate content of meals
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in Table 6.5. To summarise the results in Table 6.5, Figure 6.2 shows the blood
glucose range of the 90% condence interval and its growth over time for this
cohort. It is clear that while 1 hour prediction is easy to target due to such small
variance, 2 and 3 hourly prediction contains much more uncertainty and is thus
a potentially riskier process.
Measurement Frequency: 1 2 3
Time between 4.0-6.1 mmol L 1 46.1% 36.2% 36.4%
Time between 4.0-7.0 mmol L 1 54.5% 42.5% 46.6%
Time between 4.0-7.75 mmol L 1 59.9% 50.0% 52.5%
Time above 6 mmol L 1 36.4% 45.9% 42.8%
Time below 4 mmol L 1 18.5% 19.0% 21.6%
Time below 2.5 mmol L 1 8.7% 6.8% 5.6%
Time below 2.2 mmol L 1 3.4% 2.3% 6.4%
Mean Blood Glucose (mmol L 1) 6.1 6.8 6.4
Standard Deviation (mmol L 1) 3.1 3.6 3.6
Table 6.5 Simulation results for predictive insulin based protocol
(a) 50% condence range growth (b) 90% condence range growth
Figure 6.6 The growth in prediction range over 3 hours
6.2.1 Variable Timing
Upon close examination of Figure 6.2 it is clear that there are some periods during
which 3 hourly predictions do maintain good correspondence with the actual
observed progressions. It is these periods that we wish to isolate in variable timing
methods to reduce the burden of glycaemic control on clinical sta. Because
some probability bands become much larger over the two hourly measurements,
a variable timing scheme is tested. This approach requires a measurement to be
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Timing Options: 1-2 hourly 2-3 hourly 1-2-3 hourly
Time between 4.0-6.1 mmol L 1 37.3% 36.8% 35.7%
Time between 4.0-7.0 mmol L 1 48.9% 45.3% 47.7%
Time between 4.0-7.75 mmol L 1 55.6% 50.6% 54.1%
Time above 6 mmol L 1 39.2% 49.7% 50.8%
Time below 4 mmol L 1 24.4% 14.8% 14.9%
Time below 2.5 mmol L 1 5.3% 5.8% 4.2%
Time below 2.2 mmol L 1 1.6% 1.6% 1.7%
Mean Blood Glucose (mmol L 1) 6.8 6.5 6.9
Standard Deviation (mmol L 1) 3.3 3.2 3.3
Time of 1 hourly measurements 47.5% - 47.6%
Time of 2 hourly measurements 52.6% 73.7% 27.3%
Time of 3 hourly measurements - 26.3% 25.3%
Table 6.6 Simulation results for variable timing schemes using a large allowable band of 3
mmol L 1
taken when the probability bands become 'too large' (here dened as 3 mmol
L 1) or after the maximum period of time between measurements. The target
used is 5 mmol L 1, as used previously.
The results for this approach show signicant improvement and reduce the
clinical burden during times when uncertainty in patient response is low. A
comparison between the 1-2-3 hourly measurement control and the existing CTW
clinical practice data is shown in Figure 6.7. Table 6.6 also summarizes the results.
In all cases, hypoglycaemia and control are much improved over prior, more rigid
approaches to control.
6.3 Discussion
The simulations using a simple insulin sensitivity t appear to indicate that EIS
needs to be taken into account when modeling CTW patient behaviour. The
majority of the major hypoglycaemic events that occurred are due to large doses
of insulin being given in response to a post-prandial spike (or in anticipation
of such), which occur simultaneously alongside sharp increases in SI . It was
explained in Section 4.2.5 that the presence of EIS would be manifested in the
current model as an increasing SI and it is hypothesised that this modelling error
is the cause of this anomoly. However, even when consideration of EIS is made,
basal replacement strategies alone are inadequate to control hyperglycaemia in
the cohorts studied here, which have a greater diabetes focus.
Clearly some clinical validation of the above results is required to ensure that
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Figure 6.7 A comparison between the glucose distributions of CTW clinical data and pre-
dictive control results. Fits assume a lognormal distribution.
the inclusion of EIS is capturing the essential dynamics of the patients' glucose
system. However, these results do provide a working model for the development
of clinical trials. The initial results indicate that improved insulin therapies in a
ward setting are possible using predictive control and could potentially improve
clinical outcomes for less acutely ill ward patients. However, further studies will
have to be completed to create a user-friendly and paper based version of the
protocol.
Predictive control shows the most promise as a control strategy, but also
requires the most resources. Thus, a look up table based protocol should be
developed from the results presented here. The creation of lookup tables can be
assisted by the use of virtual patients to ensure coverage of all likely scenarios.
The results from predictive control simulations also show that 3 hourly measure-
ments are possible. However, the removal of 1 hourly measurements from the
protocol altogether result in signicant loss of tight control. It is likely that 50%
of measurements with one hour frequency would be too clinically burdensome in
a less acute ward setting. Thus, the acceptable bands may need to be widened
or reduced performance accepted if tight control is to be obtained.
From all of the results presented, it is clear that the tight glycaemic control
achieved by SPRINT in the ICU cannot be readily emulated for similar or Type I
diabetes focused cohorts in a ward setting. The inability to achieve these results is
largely due to the consumption of meals, which are varied in timing and quantity.
However, predictive control strategies do show some reduciton of hyperglycaemia
as well as a tighter glucose distribution accross the CTW cohort than is currently
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achieved clinically.

Chapter 7
Sepsis Diagnosis
Severe sepsis and septic shock has a high incidence rate and high mortality rate
in an ICU (Angus et al., 2001; Carrigan et al., 2004; Dellinger et al., 2004). The
cost of treating sepsis and of additional bed hours required in sepsis patients is
reported to be $16.7 billion dollars in the United States (Angus et al., 2001).
Insulin control protocols have been widely used to tightly control blood glucose
values (Chase et al., 2006b; Lonergan et al., 2006a; Goldberg et al., 2004b,c;
Krinsley, 2003b; Chase et al., 2006a; Van den Berghe et al., 2006b, 2001), which
has shown to result in a reduction in the incidence of sepsis (Van den Berghe
et al., 2001).
Diagnosis of sepsis presents many challenges in a clinical setting. A positive
culture should precede the use of antibiotics (Dellinger et al., 2004). However,
blood culture results take 24-48 hours, or longer, to process (Carrigan et al., 2004).
More rapid diagnosis can be achieved using a variety of biomarkers. Procalcitonin
(PCT) has been extensively investigated as such a tool, with specicity values
ranging from slighter better than random (55%) to almost perfect (88%). Tang
et al. (2007) reviewed 18 such studies and found a mean specicity of 71%, with
the upper limit of the 95% condence interval reaching only 76% (lower limit
of 67%). Balci et al. (2003) found PCT was the only marker that had a strong
negative predictive value (NPV) of 90%, as well as an 89% positive predictive
value (PPV). IL-8 was a distant second to these values, with a PPV of 53%
and NPV of 69% (Balci et al., 2003), however Harbarth et al. (2001) report
a much higher PPV of 80% and 79% for IL-6. Other biomarkers investigated
as a diagnostic by Balci include TNF, CRP, IL-6 and PCT, with even lower
diagnostic values (Balci et al., 2003).
Another problem in sepsis diagnosis is the dierentiation between sepsis and
SIRS. For this purpose, studies have found that the diagnostic value of CRP
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is greatly increased if it is considered in conjunction with C3a or to a lesser
extent C4 (immune system proteins) (Sungurtekin et al., 2006). However, for all
tests, a minimum lag time of typically 2-3 hours is still present (Carrigan et al.,
2004). Therefore, other signs must be investigated to assist in making the most
timely diagnosis and potentially starting appropriate treatments, such as uid
resuscitation, and vasopressor and inotrope use. The earlier these interventions
are correctly applied, the better the mortality outcome (Bridges and Dukes, 2005;
Rivers et al., 2001). Rivers et al. (2001) found that early goal-directed treatment
of sepsis reduced mortality from 46.5% to 30.5%.
The negative eect of sepsis on insulin sensitivity and glucose metabolism is
well documented (Agwunobi et al., 2000; Chambrier et al., 2000; Rusavy et al.,
2005). However, the mechanisms by which these changes take place are not fully
understood. It has been suggested that sepsis induces a signicant counterregu-
latory hormone response, causing the reduction in insulin sensitivity
Insulin sensitivity can be found using lumped parameter compartment models
that have had extensive clinical validation in critical care (Lonergan et al., 2006a;
Chase et al., 2006a; Wong et al., 2006; Chase et al., 2005; Lonergan et al., 2006b;
Shaw et al., 2006). In such models, varying insulin sensitivity is the driving dy-
namic. Alternatively, glycaemic control protocols usually provide some measure
of insulin sensitivity in real time. An example of one such protocol is SPRINT,
which regulates enteral nutrition rates and insulin boluses (Chase et al., 2006b;
Lonergan et al., 2006a,b). Enteral nutrition and insulin are modulated according
to the patient's current blood glucose level and the change in blood glucose level
as well as prior hour interventions, and an insulin sensitivity metric may also
be derived from these input data. This insulin sensitivity information whether
model based or estimated from intervention data is available without additional
invasive procedures, outside of those required for glucose control.
7.1 Methods
Using the cohort described in Section 3.3 - a subset of 30 patients who potentially
had sepsis during their hospital stay - comprehensive hour-by-hour clinical data
was examined to isolate the time and duration of sepsis. Every hour a value for
SI was identied creating a patient-specic and time varying prole.
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Sepsis Patients Non Sepsis Patients Total
Number of Patients 30 113 143
Total Hours 6,744 19,709 26,453
Number of Hours 2,036 5,493 7,529
in which _GT = 0
Table 7.1 Summary of patient hours in each subset of the ICU cohort
7.1.1 Sepsis Score
From the clinical data, a sepsis classication score (ss) was generated for each
hour of the patients stay that strictly follows the American College of Chest
Physicians/Society of Critical Care Medicine guideline denitions of 1992 and
2003 (ACCP, 1992; Mitchell M. Levy et al., 2003). The criteria for the sepsis
score (ss) are dened in Tables 7.2-7.4. The organ failure criteria scoring in Table
7.3 uses the most relevant elements of the denitions for the Sepsis-related Organ
Failure Assessment (SOFA) score (Vincent et al., 1996). The sepsis score thus
includes Systemic Inammatory Response Score (SIRS) and SOFA organ failure
criteria, as well as including factors for treatments indicated in sepsis. Thus,
it provides better correlation than any single criterion (Mitchell M. Levy et al.,
2003).
This sepsis score is similar to that used by Clayton et al. (2006), where a
SIRS of 3 or more was required alongside an infection or one of:
1. WBCs in a normally sterile body uid
2. Perforated viscus
3. Radiographic evidence of pneumonia with purulent sputum production
4. Strong clinical evidence of an infection without an identied pathogen.
The combination of hour-by-hour signs of infection along with a denitive di-
agnosis of infection at some point during the patient's stay is the key factor in
developing a useful sepsis score for this study. While sepsis is not a discrete pro-
cess, but rather a continuum of severity of infection, in order to generate an ROC,
some gold standard diagnosis must be assumed. To identify a clear signal, only
the most severe and clear cut instances of sepsis should be required. Thus, the
requirement of a positive culture ensures that sepsis was present at some point
during the patient stay while the use of hour by hour signs pinpoint the precise
times at which sepsis was most severe.
In Table 7.2 a tick indicates a necessary criterion and all necessary criteria
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Sepsis Score Denition
SIRS Infection Organ Fluid Inotrope High
 2 during Failure Resuscitation Use Inotrope
stay  1 Use a
0 Normal
1 Sepsis
2 Severe Sepsis
3 Septic Shock
4 Refractory
Septic Shock
a Adrenaline or Noradrenaline > 0.2 mg min  1 kg 1
Table 7.2 Sepsis Score criteria
must be present to attain the indicated score. For example, a patient only on
uid therapy resuscitation would attain a sepsis score of 0. For this study, the
gold standard diagnosis of sepsis is a sepsis score of 3 or more. This ss=3 value
corresponds to a SIRS score of 2 or more, an organ failure score of 1 or greater,
uid resuscitationtherapy and inotropic therapyinotrope use of any amount all at
the time of investigation, and an infection during the patient's ICU stay. Tables
7.3 and 7.4 dene the organ failure and SIRS scores utilized in this overall score.
Score System Criteria
+1 Cardiovascular MAP  60 mmHg
OR need for inotropes
+1 Respiratory PaO2/FiO2  250 mmHg/mmHg
 200 mmHg/mmHg
with pneumonia
+1 Renal Urine Output < 0.5 mL/kg/hr
+1 Blood Platelets < 80
OR 50% drop in 3 days
Table 7.3 Organ Failure criteria
For this 30 patient sepsis cohort, the mean APACHE II score was 22 with a
range of 7-40. The mean length of stay was 11.7 days with a range of 0.7-59 days.
The mean sepsis score for this subset was 0.5 throughout their stay. However, 45
patient hours had a sepsis score of 3 or higher at some point in their stay.
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Score Criteria
+1 Temperature  36 C
 38 C
+1 Heart Rate  90 min 1
+1 Respiratory Rate  20 min 1
OR PaCO2  32 mm Hg
+1 White Blood  4  109 L 1
Cell Count  12  109 L 1
OR presence of > 10% granulocytes
Table 7.4 SIRS criteria
7.1.2 Reciever Operating Characteristic
The denition of categorisation of all possible test outcomes is given in Table 7.5.
The ratios of positive results are dened in Equations 7.1-7.4.
Patients with Sepsis
True False
Patients with low* True True Positive (TP) False Positive (FP)
insulin sensitivity False False Negative (FN) True Negative (TN)
* Low is dened as being below a cuto value
Table 7.5 Denitions of test outcome used in the ROC generation
sensitivity =
TP
TP + FN
(7.1)
specificity =
TN
TN + FP
(7.2)
Positive Predictive V alue =
TP
TP + FP
(7.3)
Negative Predictive V alue =
TN
TN + FN
(7.4)
From the sepsis score information, a Receiver Operating Characteristic (ROC)
curve was drawn for the 30 patients using the model-based insulin sensitivity, (SI)
as the marker, and a sepsis score of ss = 3 as the diagnostic. An ROC curve plots
the sensitivity of a diagnostic test against 1-specicity, which is equivalent to the
true positive rate plotted against the false positive rate, for all possible cuto
values. A completely random test is represented as a line at 45 degrees to each
axis, representing an additional false positive result for each false negative result
eliminated. A perfect test (100% specicity and 100% sensitivity) is a vertical
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line up the sensitivity axis at 1-specicity=0 and then a horizontal line along the
1-specicity axis, allowing selection of a cuto with a zero false positive rate and
a zero false negative rate. An example of each of these extreme cases is shown
in Figure 7.1. It is expected that real diagnostic tests lie between these two lines
indicating the presence of some false positives and some false negatives. The
choice of cuto is usually that which is furtherest from the diagnonal axes, and
thus minimises the sum of both false results.
Figure 7.1 An example of an ROC with a perfectly accurate test (sensitivity=1, speci-
city=1) and a random test (sensitivity=0.5, specicity=0.5)
7.1.3 Simple Insulin Sensitivity
The generate ROC curve is compared to the estimated insulin sensitivity iden-
tied by the SPRINT protocol, referred to as simple insulin sensitivity or SSI .
This approximated insulin sensitivity is evaluated only at times that the change
in glucose is less than the measurement error of 7% (Arkray, 2001) (ie. _G = 0 ).
The formula for SSI is given by Equation 7.5 and the derivation of this term is
shown below. Starting from Equation 4.1 and setting _G = 0 gives:
0 =  pGG  SIQ;effG+ P (t) + EGP
Then, assuming endogenous glucose clearance and production is small rst equa-
tion above becomes:
0 =  SIQ;effG+ P (t)
The nal assumption made is that Q;eff is entirely inuenced by exogenous inputs
and thus has no saturation eects. This assumption implies that the eect of
insulin administered previously is small compared to the current insulin input,
which means that SSI will be a more accurate measure of insulin sensitivity
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during large exogenous insulin inputs. Finally, simple algebraic rearrangement
results in the following denition:
SI =
P (t)
Q;effG
This denition is an approximated SI value when glucose is in a steady state.
We can then write the metric identied, as shown in Equation 7.5.
SSI =
60P (t)
I(t)G
(7.5)
In evaluating this metric, when blood glucose is not available at any hour, the
last reading taken is used. The number of patient hours that satisfy the _G = 0
criteria are shown in Table 7.1.
Alternatively, the combined estimated eect of EGP and CNS could be added
to the P (t) factor. However, this choice would serve only to scale the curve unless
patient specic values were availale. The implications of the curve are calibrated
by empirical data and thus this process would unnecessarily add complexity to
the calculation of SSI , as no additional diagnostic power would be gained.
7.2 Results
Figure 7.2 and Table 7.6 shows the insulin sensitivity distributions for 130 patients
compared with APACHE II score, discretising the patient set into 9 groups of
APACHE II scores. Note that the remaining 13 patients are not included in the
APACHE II score groups due to unavailable APACHE II score data. None of
these 13 were in the 30 patient sepsis cohort. Figure 7.2 shows the high density
of low SI readings found in all groups with APACHE II greater than 6.
The ROC curve for model-based SI data from 6744 patient hours is shown
in Figure 7.3. The sensitivity of the insulin sensitivity test was found to be
77.8% and the specicity, 82.2%. The positive predictive value was 2.8% and the
negative predictive value was 99.8%. The cuto value for this test was an SI
of 810 5 L mU 1 min 1. Over 85% of the 26,453 identied insulin sensitivity
values for the general ICU cohort (143 patients, with and without sepsis) were
above the 810 5 L mU 1 min 1 cuto.
Over 85% of the time, an ICU patient's insulin sensitivity will be above the
cuto point of 810 5 L mU 1 min 1 as found from tting the 26,453 hours of
the 143 general overall ICU patient cohort employed.
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Figure 7.2 Insulin Sensitivity (SI) distributions of ICU patients grouped by APACHE II
scores
Insulin sensitivity distributions were compared with APACHE II score, dis-
cretising the patient set into 9 groups of APACHE II scores. The results for 130
patients are shown in Figure 2 and Table 7.6. Note that the remaining 13 patients
are not included in the APACHE II score groups due to unavailable APACHE II
score data. None of these 13 were in the 30 patient sepsis cohort.
The SSI ROC curve for the applicable 2036 patient hours that _G = 0 is
shown in Figure 7.4. The sensitivity of the insulin sensitivity test was found to
be 68.8% and the specicity, 81.7%. The positive predictive value was 2.9% and
the negative predictive value was 99.7%. The cuto value for this test was an
SSI of 2.810 4 L mU 1, which is approximately 3 times higher than that for SI
in Figure 12. For 82.7% of the time, an ICU patient's simple insulin sensitivity
(SSI) will be above this cuto point of 2.810
 4 L mU 1 as found from the 7529
hours of the 143 general ICU patient cohort (28% of 26,453 available hours). This
82.7% result is similar to the result for SI over the full time period.
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APACHE II Percentage of time
score range below cuto
1 - 5 2.3
6 - 10 15.3
11 - 15 8.7
16 - 20 12.7
21 - 25 14.8
26 - 30 15.3
31 - 35 20
36 - 40 15.3
41 - 45 19.8
Table 7.6 Time spent below SI = 8  10
 5 L mU 1 min 1, the cuto value for ss 3
7.3 Discussion
Absence of sepsis shows a strong correlation with a higher SI . The ROC shown
in Figure 7.3 indicates that insulin sensitivity can exclude a sepsis diagnosis far
more accurately than it can make one. Specically, 87% of the time in this ICU
cohort it is 99.8% certain that a patient does not have sepsis (ss = 2) due to a
modeled insulin sensitivity of greater than 810 5 L mU 1 min 1.
However, as a positive predictor, insulin sensitivity is not applicable. Figure
7.2 shows that with increasing APACHE II scores, the lognormal distribution of
SI tends to lower SI values (Kruskal-Wallis Test p<0.05). This result indicates
that not only sepsis, but other severe illness and eects could be responsible for
a low SI value in a critically ill patient, causing a high number of false positives.
This result explains the low positive predictive value of either insulin sensitivity
metric (SI or SSI).
The SSI was an inferior predictor to the model based SI proles, but the
negative predictive value was still very high oering the possibility of ruling out
sepsis in 82.7% of patient hours. However, with additional data the cut-o point
identied by the ROC may move signicantly, but these predictive values should
only change slightly. A limiting factor in this analysis is that only 16 septic patient
patient hours with sepsis, out of 2036 patient hours, were available for this part
of the study. This limited quantity of data is due to the requirements of non-zero
feed enteral nutrition and insulin input and negligible changes in blood glucose
for Equation 7.5. Overall, only approximately 30% of patient hours (30.2% of
patient hours in the sepsis cohort and 32% in the complete cohort) were available
to compute SSI and 32% in the complete cohort, creating a potential further
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Figure 7.3 ROC of Modeled Insulin Sensitivity (SI) as a predictor of Sepsis (ss 3)
limitation for the simpler metric.
While the sensitivity of the test remained relatively unchanged for SSI versus
SI , the specicity dropped greatly due to a large increase in the number of false
positives. This result can be partly explained by the protocol's reduced resolution.
However, it is possible that another eect is due to the pool of data being reduced
by the requirement that change in measured glucose is less than 7% of previous
measurement (measurement error). Constant blood glucose is more likely to
be found in more stable patients who are generally less likely to have sepsisbe
septic. This unintended ltering in using the simplied SSI metric increases the
proportion of patients with low baseline insulin sensitivity, to patients with sepsis
induced low insulin sensitivity. In particular, 40% of septic hours with sepsis in
the sepsis cohort were eliminated by the criterion. This ltering also causes the
discretised appearance of the ROC curve, by reducing the number of available
data points, particularly periods of sepsis.
However, the 1 U hr 1 insulin requirement for the estimated metric is not
as restrictive in an ICU as in a less acute ward setting. A 1 U hr 1 or greater
insulin dosage is frequently called for in glycaemic control protocols and is often
sustained for prolonged periods of a patients' hyperglycaemic stay. Similarly,
patients will typically not spend signicant periods of time fasting in an ICU.
For this study, only enteral feed nutrition was considered as oral and parenteral
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Figure 7.4 ROC of Insulin Sensitivity (SSI) evaluated in real time as a predictor of Sepsis
feed nutrition were not used.
The advantage of SSI as a predictor is that it can be very easily evaluated
in real time with only a pocket calculator. Hence, a clinician can obtain useful
information about a patient's condition without invasive, computationally inten-
sive or time consuming tests. While the simple method introduces additional
uncertainty by reduced resolution, as well as oering limited availability, the re-
duction in computational eort could justify its use over a model based approach
if the computational resources were not available (eg. A PDA with program).
A growing trend toward computation driven protocols is occurring which could
lead towards the regular use of a modeled SI value (Chase et al., 2006a; Plank
et al., 2006; Shulman et al., 2007; Thomas et al., 2005).
Figure 4 shows the correlation between model SI and SSI . The R
2 value for
the relationship is 0.68. This stronger correlation supports the similarity between
the ndings of the SI and SSI diagnostics, despite the small amount of sepsis
hours available for the latter. This comparison between insulin sensitivities is for
7529 hours of the general ICU cohort of 143 patients. The comparison includes
times when blood glucose values are changing by less than 7% and when insulin
received is greater than 1 U hr 1. The latter constraint is applied to include
only times when EGP is suciently suppressed. If the requirement is extended
to those times at which a patient receives 1.5 U hr 1 of insulin, the R2 value
increases to 0.78 by eliminating the outliers as shown. Additionally, the model SI
t limits the values to 1  10 5 L mU 1 min 1 = SI = 1 10
 3 L mU 1 min 1,
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whereas SSI is unrestricted in value. These dierent limits have also reduced the
correlation between SI and SSI .
With the discretised nature of the gold standard sepsis denition used (ss =
3), it is clear that some error must be present in the gold standard used in the
derivation of the ROC curves. This error may limit the reliability of the results.
However, with limited blood culture and biomarker data available due to the
retrospective nature of the study, this error was unavoidable.
Patients who have Type I or Type II diabetes are excluded from this study.
If these patients were to be included it is likely that the sensitivity and predictive
value would be even lower than at present since these patients will present with
insulin resistance (at least, in Type II diabetics). The prevalence of Type II
diabetes is high and disproportionately so in an ICU (King et al., 1998; Umpierrez
et al., 2002), and is expected that Type II diabetics will have longer hospital stays
due to increased insulin resistance, further limiting the clinical applications of this
study.
Figure 7.5 shows an example of ss over time in comparison with SI . The
shaded areas represent a diagnosis of sepsis according to the respective param-
eters. It can be seen that during the initial 48 hours of the patients stay, SI is
very low and ss peaks multiple times during this period. At all other times, ss
is 1 or less, and SI rarely falls below the cuto value.
Figure 7.5 An example of ss and SI variance over time
Chapter 8
Conclusions
This study has presented the variable nature of patient's glycaemic stability in
a less acute ward. Modications to a standard ICU model have been made to
identify the limited endogenous insulin secretion that such patients are likely to
display in response to consumption of a meal. This model has not been validated.
From the glycaemic data of 7 CTW patients a stochastic model was generated
and validated against a subcohort of 131 stable ICU patients. Model convergence
was not observed, most likely due to the increased range of insulin sensitivity
observed. This stochastic model was used in predictive control for varied and
lengthened intervention periods. The amount of data available which is
The simulation results on 7 CTW patients reveal that glycaemic levels in
the ward cannot be adequately controlled by a SPRINT based system, nor by
meal boluses. Due to the highly variable nature of insulin sensitivity, which is
aected by such a wide range of factors, no accurate delivery of insulin dose is
possible without considering the progression of the probability bounds and us-
ing predictive control strategies. However, while the simulation results illustrate
tighter control than what was clinically obtained during the patients' stay, there
is a unacceptably high rate of hypoglycaemia (4% below 2.5 mmol L 1). It is
uncertain if such high hypoglycaemic episodes Even so, glycaemic variability (and
thus uncertainty) was found to increase with increasing time between measure-
ments, limiting the success of predictive control. Thus, it is likely that in order
to provide glycaemic control to a ward in a safe and time-ecient manner some
compromise on performance in hyperglycaemia reduction will have to be made.
Insulin sensitivity was found to be a good diagnostic marker of the absence
of sepsis in an ICU cohort - high insulin sensitivity can rule out the presence of
sepsis in a critically-ill non-diabetic patient for the majority of their stay. Sepsis
is ruled out when modelled insulin sensitivity is above SI = 8  10
 5 L mU 1.
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This condition is met for 85% of all patient hours in this general ICU setting.
Insulin sensitivity below 8  10 5 L mU 1 min 1 can be due to either sepsis or
other underlying conditions. The accuracy and exibility of model based insulin
sensitivity gives better reliability as a diagnostic for sepsis. However, insulin
sensitivity can be reasonably accurately evaluated using estimated methods in
real time by using glycaemic control protocol data. These estimated values pro-
vide similar negative predictive values. This study shows the potential of insulin
sensitivity as a diagnostic metric for sepsis when used as a negative predictor,
however it will also require a larger validation study including more complete
blood culture data to fully validate it for clinical use.
Chapter 9
Future Work
This paper has presented a framework for investigating the introduction of a
glycaemic control strategy into less acute wards. While, no satisfactory means of
avoiding the risk of hypoglycaemia has been found, there are some benets to be
gained from the results found.
Additional data of patients from the less acute wards would greatly assist the
understanding of typical population characteristics. If more data was available
to the generation of the stochastic model, greater reliability would be evident in
predictive control. Similarly, simulation of glycaemic control on a larger cohort
might give better estimates of how a general ward population would respond to
any treatment strategies.
No validation of the model used in this study has been conducted. It is pos-
sible that the model is overestimating hypoglycaemic episodes since the increase
in EGP that should arise from low glucose levels is not modelled. Clinical trials
using a much less agressive means of control, such as the Treat-to-Target protocol
utilising glargine and no meal boluses would indicate if such incidences are being
overestimated without risking patient safety. If the results of such trials allow for
the consideration of increasing EGP then this mechanism can be easily included
in the model and greater control obtained from the increased reliability. How-
ever, it would be unwise to trial a protocol using variable EGP without further
validation when it is clear from the results presented that neglecting the variance
indicates that severe hypoglycaemia would result.
There are some unexplored avenues in control strategy which may also justify
further investigation. The target set in predictive control signicantly aects the
outcome, as expected. Thus, experimentation with dierent targets may yield a
more clinically viable control strategy. Similarly, insulin could be limited when
the 5% condence band falls below 4 mmol L 1.
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Meal boluses are typically very eective in the management of diabetes, how-
ever a rigid protocol has shown little success in this research. Possibly this is
due to a lack of patient specic doses. That is, insulin sensitivity is not taken
into account when determining the bolus, only the blood glucose level. Simi-
larly, no progression of patient condition is allowed for. Thus, developing a more
exible and responsive controller of meal boluses many signicantly reduce the
post-prandial peaks of blood glucose.
There are many aspects of regular meal consumption that have not been
investigated here, particularly in relation to predictive control. The consumption
of meals should be included in the predictions using expected values of glucose rise
and fall from a meals. Similarly, some estimate of the likely endogenous insulin
secretions should improve the viability of glycaemic control. Such estimates of
EIS will need to be patient specic to account for the signicant variance in -cell
function observed in the varying levels diabetes or insulin-resistance.
Some analysis of the eect of errors in meal estimates is also essential to devel-
oping a working protocol. Such sensitivity analyses would give greater protection
against hypoglycaemic incidences in the event of miscalculation of carbohydrate
intakes.
This study has presented insulin sensitivity models and tools for use in a clin-
ical setting based upon critically ill and less acutely ill patients. The diagnostic
value of insulin sensitivity measures may be further improved by better sepsis
criteria. At present, the discretisation of a gold standard diagnosis of sepsis indi-
cates that sepsis is rapidly switching between presence and absence on an hourly
basis. Smoothing of sepsis score data or improved logical criteria for a diagnosis
may prevent this and identify periods rather than hours during which sepsis is
present. With this improved accuracy, the positive predictive value of SI and
SSI is likely to improve and a new cuto value will be found.
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